<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">PLoS Genet</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosgen</journal-id>
<journal-title-group>
<journal-title>PLoS Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1553-7390</issn>
<issn pub-type="epub">1553-7404</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28957316</article-id>
<article-id pub-id-type="pmc">5619689</article-id>
<article-id pub-id-type="doi">10.1371/journal.pgen.1006915</article-id>
<article-id pub-id-type="publisher-id">PGENETICS-D-16-02674</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Mutation</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Genetic Loci</subject>
<subj-group>
<subject>Alleles</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and Analysis Methods</subject>
<subj-group>
<subject>Simulation and Modeling</subject>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>People and Places</subject>
<subj-group>
<subject>Geographical Locations</subject>
<subj-group>
<subject>Europe</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Population Biology</subject>
<subj-group>
<subject>Population Metrics</subject>
<subj-group>
<subject>Population Size</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Mutation</subject>
<subj-group>
<subject>Deletion Mutation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Cell biology</subject>
<subj-group>
<subject>Chromosome biology</subject>
<subj-group>
<subject>Chromatin</subject>
<subj-group>
<subject>Chromatin modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Epigenetics</subject>
<subj-group>
<subject>Chromatin</subject>
<subj-group>
<subject>Chromatin modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Gene expression</subject>
<subj-group>
<subject>Chromatin</subject>
<subj-group>
<subject>Chromatin modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>DNA</subject>
<subj-group>
<subject>DNA modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Nucleic acids</subject>
<subj-group>
<subject>DNA</subject>
<subj-group>
<subject>DNA modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Epigenetics</subject>
<subj-group>
<subject>DNA modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Gene expression</subject>
<subj-group>
<subject>DNA modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and Analysis Methods</subject>
<subj-group>
<subject>Database and Informatics Methods</subject>
<subj-group>
<subject>Biological Databases</subject>
<subj-group>
<subject>Mutation Databases</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Mutation</subject>
<subj-group>
<subject>Mutation Databases</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The population genetics of human disease: The case of recessive, lethal mutations</article-title>
<alt-title alt-title-type="running-head">The population genetics of recessive, lethal mutations</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8827-238X</contrib-id>
<name>
<surname>Amorim</surname>
<given-names>Carlos Eduardo G.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Ziyue</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baker</surname>
<given-names>Zachary</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Diesel</surname>
<given-names>José Francisco</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Simons</surname>
<given-names>Yuval B.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haque</surname>
<given-names>Imran S.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref>
<xref ref-type="author-notes" rid="currentaff001">
<sup>¤</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pickrell</surname>
<given-names>Joseph</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff007">
<sup>7</sup>
</xref>
<xref ref-type="author-notes" rid="econtrib001">
<sup>‡</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Przeworski</surname>
<given-names>Molly</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="econtrib001">
<sup>‡</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label>
<addr-line>Department of Biological Sciences, Columbia University, New York, NY, United States of America</addr-line></aff>
<aff id="aff002"><label>2</label>
<addr-line>CAPES Foundation, Ministry of Education of Brazil, Brasília, DF, Brazil</addr-line></aff>
<aff id="aff003"><label>3</label>
<addr-line>Howard Hughes Medical Institution, Stanford University, Stanford, CA, United States of America</addr-line></aff>
<aff id="aff004"><label>4</label>
<addr-line>Department of Systems Biology, Columbia University, New York, NY, United States of America</addr-line></aff>
<aff id="aff005"><label>5</label>
<addr-line>Universidade Federal de Santa Maria, Santa Maria, RS, Brazil</addr-line></aff>
<aff id="aff006"><label>6</label>
<addr-line>Counsyl, 180 Kimball Way, South San Francisco, CA, United States of America</addr-line></aff>
<aff id="aff007"><label>7</label>
<addr-line>New York Genome Center, New York, NY, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>Messer</surname>
<given-names>Philipp W.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"></xref>
</contrib>
</contrib-group>
<aff id="edit1">
<addr-line>Cornell University, UNITED STATES</addr-line>
</aff>
<author-notes>
<fn fn-type="COI-statement" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="current-aff" id="currentaff001">
<label>¤</label>
<p>Current address: Freenome, South San Francisco, CA, United States of America</p>
</fn>
<fn fn-type="other" id="econtrib001">
<p>‡ These authors co-supervised this work.</p>
</fn>
<corresp id="cor001">* E-mail: <email>guerraamorim@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>9</month>
<year>2017</year>
</pub-date>
<volume>13</volume>
<issue>9</issue>
<elocation-id>e1006915</elocation-id>
<history>
<date date-type="received">
<day>4</day>
<month>12</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>7</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© 2017 Amorim et al</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Amorim et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="pgen.1006915.pdf"></self-uri>
<abstract>
<p>Do the frequencies of disease mutations in human populations reflect a simple balance between mutation and purifying selection? What other factors shape the prevalence of disease mutations? To begin to answer these questions, we focused on one of the simplest cases: recessive mutations that alone cause lethal diseases or complete sterility. To this end, we generated a hand-curated set of 417 Mendelian mutations in 32 genes reported to cause a recessive, lethal Mendelian disease. We then considered analytic models of mutation-selection balance in infinite and finite populations of constant sizes and simulations of purifying selection in a more realistic demographic setting, and tested how well these models fit allele frequencies estimated from 33,370 individuals of European ancestry. In doing so, we distinguished between CpG transitions, which occur at a substantially elevated rate, and three other mutation types. Intriguingly, the observed frequency for CpG transitions is slightly higher than expectation but close, whereas the frequencies observed for the three other mutation types are an order of magnitude higher than expected, with a bigger deviation from expectation seen for less mutable types. This discrepancy is even larger when subtle fitness effects in heterozygotes or lethal compound heterozygotes are taken into account. In principle, higher than expected frequencies of disease mutations could be due to widespread errors in reporting causal variants, compensation by other mutations, or balancing selection. It is unclear why these factors would have a greater impact on disease mutations that occur at lower rates, however. We argue instead that the unexpectedly high frequency of disease mutations and the relationship to the mutation rate likely reflect an ascertainment bias: of all the mutations that cause recessive lethal diseases, those that by chance have reached higher frequencies are more likely to have been identified and thus to have been included in this study. Beyond the specific application, this study highlights the parameters likely to be important in shaping the frequencies of Mendelian disease alleles.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author summary</title>
<p>What determines the frequencies of disease mutations in human populations? To begin to answer this question, we focus on one of the simplest cases: mutations that cause completely recessive, lethal Mendelian diseases. We first review theory about what to expect from mutation and selection in a population of finite size and generate predictions based on simulations using a plausible demographic scenario of recent human evolution. For a highly mutable type of mutation, transitions at CpG sites, we find that the predictions are close to the observed frequencies of recessive lethal disease mutations. For less mutable types, however, predictions substantially under-estimate the observed frequency. We discuss possible explanations for the discrepancy and point to a complication that, to our knowledge, is not widely appreciated: that there exists ascertainment bias in disease mutation discovery. Specifically, we suggest that alleles that have been identified to date are likely the ones that by chance have reached higher frequencies and are thus more likely to have been mapped. More generally, our study highlights the factors that influence the frequencies of Mendelian disease alleles.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>CAPES Foundation, Science Without Borders</institution>
</funding-source>
<award-id>BEX 8279/11-0</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8827-238X</contrib-id>
<name>
<surname>G. Amorim</surname>
<given-names>Carlos Eduardo</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution>CNPq</institution>
</funding-source>
<award-id>PDE 201145/2015-4</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8827-238X</contrib-id>
<name>
<surname>G. Amorim</surname>
<given-names>Carlos Eduardo</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution>Stanford Center for Computational, Evolutionary and Human Genomics</institution>
</funding-source>
<principal-award-recipient>
<name>
<surname>Gao</surname>
<given-names>Ziuye</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution>CAPES Foundation, Science Without Borders</institution>
</funding-source>
<award-id>88888.038761/2013-00</award-id>
<principal-award-recipient>
<name>
<surname>Diesel</surname>
<given-names>José Francisco</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award005">
<funding-source>
<institution>Research Initiative in Science and Engineering</institution>
</funding-source>
<principal-award-recipient>
<name>
<surname>Pickrell</surname>
<given-names>Joseph</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award006">
<funding-source>
<institution>Research Initiative in Science and Engineering</institution>
</funding-source>
<principal-award-recipient>
<name>
<surname>Przeworski</surname>
<given-names>Molly</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award007">
<funding-source>
<institution>National Institutes of Health (US)</institution>
</funding-source>
<award-id>S10OD012351</award-id>
</award-group>
<award-group id="award008">
<funding-source>
<institution>National Institutes of Health (US)</institution>
</funding-source>
<award-id>S10OD021764</award-id>
</award-group>
<award-group id="award009">
<funding-source>
<institution>National Institute of General Medical Sciences (US)</institution>
</funding-source>
<award-id>GM121372</award-id>
<principal-award-recipient>
<name>
<surname>Przeworski</surname>
<given-names>Molly</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award010">
<funding-source>
<institution>National Institute of General Medical Sciences (US)</institution>
</funding-source>
<award-id>GM121372</award-id>
<principal-award-recipient>
<name>
<surname>Pickrell</surname>
<given-names>Joseph</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>CEGA was partially funded by a Science Without Borders fellowship from CAPES foundation (BEX 8279/11-0) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (PDE 201145/2015-4), Brazil. ZG was partially supported by a postdoctoral fellowship funded by Stanford Center for Computational, Evolutionary and Human Genomics. JFD was funded by a Science Without Borders fellowship from CAPES foundation (88888.038761/2013-00). YBS was supported by NIH grant GM115889. The work was partially supported by a Research Initiative in Science and Engineering grant from Columbia University and NIGMS grants (GM121372) to JKP and MP. The computing in this project was supported by two National Institutes of Health instrumentation grants (S10OD012351 and S10OD021764) received by the Department of Systems Biology at Columbia University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="1"></table-count>
<page-count count="23"></page-count>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files and code from gitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/cegamorim/PopGenHumDisease">https://github.com/cegamorim/PopGenHumDisease</ext-link>; <ext-link ext-link-type="uri" xlink:href="https://github.com/sellalab/ForwardSimulator">https://github.com/sellalab/ForwardSimulator</ext-link>).</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<title>Data Availability</title>
<p>All relevant data are within the paper and its Supporting Information files and code from gitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/cegamorim/PopGenHumDisease">https://github.com/cegamorim/PopGenHumDisease</ext-link>; <ext-link ext-link-type="uri" xlink:href="https://github.com/sellalab/ForwardSimulator">https://github.com/sellalab/ForwardSimulator</ext-link>).</p>
</notes>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>New disease mutations arise in heterozygotes and either drift to higher frequencies or are rapidly purged from the population, depending on the strength of selection and the demographic history of the population [<xref ref-type="bibr" rid="pgen.1006915.ref001">1</xref>–<xref ref-type="bibr" rid="pgen.1006915.ref006">6</xref>]. Elucidating the relative contributions of mutation, natural selection and genetic drift will help to understand why disease alleles persist in humans. Answers to these questions are also of practical importance, in informing how genetic variation data can be used to identify additional disease mutations [<xref ref-type="bibr" rid="pgen.1006915.ref007">7</xref>].</p>
<p>In this regard, rare, Mendelian diseases, which are caused by single highly penetrant and deleterious alleles, are perhaps most amenable to investigation. A simple model for the persistence of mutations that lead to Mendelian diseases is that their frequencies reflect an equilibrium between their introduction by mutation and elimination by purifying selection, i.e., that they should be found at “mutation-selection balance” [<xref ref-type="bibr" rid="pgen.1006915.ref004">4</xref>]. In finite populations, random drift leads to stochastic changes in the frequency of any mutation, so demographic history, in addition to mutation and natural selection, plays an important role in shaping the frequency distribution of deleterious mutations [<xref ref-type="bibr" rid="pgen.1006915.ref003">3</xref>].</p>
<p>Another factor that may be important in determining the frequencies of highly penetrant disease mutations is genetic interactions. The mutation-selection balance model has been extended to scenarios with more than one disease allele, as is often seen for Mendelian diseases [<xref ref-type="bibr" rid="pgen.1006915.ref008">8</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref009">9</xref>]. When compound heterozygotes have the same fitness as homozygotes for the disease allele (i.e., there is no complementation), the combined frequency of all disease alleles can be modeled similarly as the bi-allelic case, with the mutation rate given by the sum of the mutation rate to each disease allele [<xref ref-type="bibr" rid="pgen.1006915.ref008">8</xref>]. In other cases, a disease mutation may be rescued by another mutation in the same gene [<xref ref-type="bibr" rid="pgen.1006915.ref010">10</xref>–<xref ref-type="bibr" rid="pgen.1006915.ref012">12</xref>] or by a modifier locus elsewhere in the genome that modulates the severity of the disease symptoms or the penetrance of the disease allele (e.g. [<xref ref-type="bibr" rid="pgen.1006915.ref013">13</xref>–<xref ref-type="bibr" rid="pgen.1006915.ref015">15</xref>]).</p>
<p>For a subset of disease alleles that are recessive, an alternative model for their persistence in the population is that there is an advantage to carrying one copy but a disadvantage to carrying two or none, such that the alleles persist due to overdominance, a form of balancing selection. Well known examples include sickle cell anemia, thalassemia and G6PD deficiency in populations living where malaria exerts strong selection pressures [<xref ref-type="bibr" rid="pgen.1006915.ref016">16</xref>]. The importance of overdominance in maintaining the high frequency of disease mutations is unknown beyond these specific cases.</p>
<p>Here, we tested hypotheses about the persistence of mutations that cause lethal, recessive, Mendelian disorders. This case provides a good starting point, because a large number of Mendelian disorders have been mapped (e.g., genes have already been associated with &gt;56% of Mendelian disease phenotypes; [<xref ref-type="bibr" rid="pgen.1006915.ref017">17</xref>]). Moreover, while the fitness effects of most diseases are hard to estimate, for recessive lethal diseases, the selection coefficient is clearly 1 for homozygote carriers in the absence of modern medical care (which, when available, became so only in the last couple of generations, a timescale that is much too short to substantially affect disease allele frequencies). Moreover, assuming mutation-selection balance in an infinite population and no effects in heterozygotes would suggest that, given a per base pair (bp) mutation rate <italic>u</italic> on the order of 10<sup>−8</sup> per generation [<xref ref-type="bibr" rid="pgen.1006915.ref018">18</xref>], the frequency of such alleles would be <inline-formula id="pgen.1006915.e001"><alternatives><graphic id="pgen.1006915.e001g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e001.jpg"></graphic><mml:math id="M1"><mml:mrow><mml:msqrt><mml:mi>u</mml:mi></mml:msqrt></mml:mrow></mml:math></alternatives></inline-formula>, i.e., ~10<sup>−4</sup> [<xref ref-type="bibr" rid="pgen.1006915.ref004">4</xref>]. Thus, sample sizes in human genetics are now sufficiently large that we should be able to observe completely recessive, lethal disease alleles segregating in heterozygote carriers.</p>
<p>To this end, we compiled genetic information for a set of 417 mutations reported to cause fatal, recessive Mendelian diseases and estimated the frequencies of the disease-causing alleles from large exome datasets. We then compared these data to the expected frequencies of deleterious alleles based on models of mutation-selection balance in order to evaluate the effects of mutation rates and other factors in influencing these frequencies.</p>
</sec>
<sec id="sec002" sec-type="results">
<title>Results</title>
<sec id="sec003">
<title>Mendelian recessive disease allele set</title>
<p>We relied on two datasets, one that describes 173 autosomal recessive diseases [<xref ref-type="bibr" rid="pgen.1006915.ref019">19</xref>] and another from a genetic testing laboratory (Counsyl [<xref ref-type="bibr" rid="pgen.1006915.ref020">20</xref>]; &lt;<ext-link ext-link-type="uri" xlink:href="https://www.counsyl.com/">https://www.counsyl.com/</ext-link>&gt;) that includes 110 recessive diseases of clinical interest. From these lists, we obtained a set of 44 “recessive lethal” diseases associated with 45 genes (<xref ref-type="supplementary-material" rid="pgen.1006915.s001">S1 Table</xref>), requiring that at least one of the following conditions is met: (i) in the absence of treatment, the affected individuals die of the disease before reproductive age, (ii) reproduction is completely impaired in patients of both sexes, (iii) the phenotype includes severe mental retardation that in practice precludes reproduction, or (iv) the phenotype includes severely compromised physical development, again precluding reproduction.</p>
<p>Based on clinical genetics datasets and the medical literature (see <xref ref-type="sec" rid="sec009">Methods</xref> for details), we were able to confirm that 417 Single Nucleotide Variants (SNVs) in 32 (of the 44) genes had been reported with compelling evidence of association to the severe form of the corresponding disease and an early-onset, as well as no indication of effects in heterozygote carriers (<xref ref-type="supplementary-material" rid="pgen.1006915.s002">S2 Table</xref>). By this approach, we obtained a set of mutations for which, at least in principle, there is no heterozygote effect, i.e., for which the dominance coefficient <italic>h</italic> = 0 in a model with relative fitness of 1 for the homozygote for the reference allele, 1-<italic>hs</italic> for the heterozygote, and 1-<italic>s</italic> for the homozygote for the deleterious allele, and the selective coefficient <italic>s</italic> is 1.</p>
<p>A large subset of these mutations (29.3%) consists of transitions at CpG sites (henceforth CpGti), which occur at a highly elevated rates (~17-fold higher on average) compared to other mutation types, namely CpG transversions, and non-CpG transitions and transversions [<xref ref-type="bibr" rid="pgen.1006915.ref018">18</xref>]. This proportion is in agreement with previous estimates for a smaller set of disease genes [<xref ref-type="bibr" rid="pgen.1006915.ref021">21</xref>] and for <italic>DMD</italic> [<xref ref-type="bibr" rid="pgen.1006915.ref022">22</xref>].</p>
</sec>
<sec id="sec004">
<title>Empirical distribution of allele frequencies of disease mutations in Europe</title>
<p>Allele frequency data for the 417 variants were obtained from the Exome Aggregation Consortium (ExAC) for 60,706 individuals, of whom 33,370 are non-Finnish Europeans [<xref ref-type="bibr" rid="pgen.1006915.ref023">23</xref>]. Out of the 417 variants associated with putative recessive lethal diseases, three were found homozygous in at least one individual in this dataset (rs35269064, p.Arg108Leu in <italic>ASS1</italic>; rs28933375, p.Asn252Ser in <italic>PRF1</italic>; and rs113857788, p.Gln1352His in <italic>CFTR</italic>). Available data quality information for these variants does not suggest genotype calling artifacts (<xref ref-type="supplementary-material" rid="pgen.1006915.s002">S2 Table</xref>). Since these diseases have severe symptoms that lead to early death without treatment and these ExAC individuals are healthy (i.e., do not manifest severe Mendelian diseases) [<xref ref-type="bibr" rid="pgen.1006915.ref023">23</xref>], the reported mutations are likely errors in pathogenicity classification or cases of incomplete penetrance (see a similar observation for <italic>CFTR</italic> and <italic>DHCR7</italic> in [<xref ref-type="bibr" rid="pgen.1006915.ref024">24</xref>]). We therefore excluded them from our analyses. In addition to the mutations present in homozygotes, we also filtered out sites that had lower coverage in ExAC (see <xref ref-type="sec" rid="sec009">Methods</xref>), resulting in a final dataset of 385 variants in 32 genes (<xref ref-type="supplementary-material" rid="pgen.1006915.s002">S2 Table</xref>).</p>
<p>Genotypes for a subset (91) of these mutations were also available for a larger sample size (76,314 individuals with self-reported European ancestry) generated by the company Counsyl (<xref ref-type="supplementary-material" rid="pgen.1006915.s003">S3 Table</xref>). A comparison of the allele frequencies in this larger dataset to that of ExAC suggests that the allele frequencies for individual variants are concordant between the two datasets (Pearson’s correlation coefficient of 0.79, <xref ref-type="supplementary-material" rid="pgen.1006915.s006">S1 Fig</xref>) and that the overall distributions do not differ appreciably (Kolmogorov–Smirnov test, p-value = 0.23). Thus, both data sets appear to reflect the general distribution of these disease alleles in Europeans. In what follows, we focused on ExAC, which includes a greater number of disease mutations.</p>
</sec>
<sec id="sec005">
<title>Models of mutation-selection balance</title>
<p>To generate expectations for the frequencies of these disease mutations under mutation-selection balance, we considered models of infinite and finite populations of constant size [<xref ref-type="bibr" rid="pgen.1006915.ref003">3</xref>] and conducted forward simulations using a plausible demographic model for African and European populations [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>] (see <xref ref-type="sec" rid="sec009">Methods</xref> for details). In all these models, there is a wild-type allele (A) and a deleterious allele (a, which could also represent a class of distinct deleterious alleles with the same fitness effect) at each site, such that the relative fitness of individuals of genotypes AA, Aa, or aa is given respectively by:</p>
<list list-type="bullet">
<list-item>
<p><italic>w</italic><sub><italic>AA</italic></sub> = 1;</p>
</list-item>
<list-item>
<p><italic>w</italic><sub><italic>Aa</italic></sub> = 1-<italic>hs</italic>;</p>
</list-item>
<list-item>
<p><italic>w</italic><sub><italic>aa</italic></sub> = 1-<italic>s</italic>;</p>
</list-item>
</list>
<p>The mutation rate from A to a is <italic>u;</italic> we assume that there are no back mutations.</p>
<p>For a constant population of infinite size, Wright [<xref ref-type="bibr" rid="pgen.1006915.ref026">26</xref>] showed that under these conditions, there exists a stable equilibrium between mutation and selection, when the selection pressure is sufficiently strong (<italic>s</italic>&gt;&gt;<italic>u</italic>). In particular, when the deleterious effect of allele a is completely recessive (<italic>h</italic> = 0), its equilibrium frequency <italic>q</italic> is given by:
<disp-formula id="pgen.1006915.e002"><alternatives><graphic id="pgen.1006915.e002g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e002.jpg"></graphic><mml:math id="M2"><mml:mrow><mml:mi>q</mml:mi><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:mi>u</mml:mi><mml:mo>/</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msqrt><mml:mo>.</mml:mo></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula></p>
<p>For a <italic>finite</italic> population of constant size, Nei [<xref ref-type="bibr" rid="pgen.1006915.ref003">3</xref>] derived the mean (<xref ref-type="disp-formula" rid="pgen.1006915.e003">Eq 2</xref>) and variance (<xref ref-type="disp-formula" rid="pgen.1006915.e004">Eq 3</xref>) of the frequency of a fully recessive deleterious mutation (<italic>h</italic> = 0) based on a diffusion model, leading to:
<disp-formula id="pgen.1006915.e003"><alternatives><graphic id="pgen.1006915.e003g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e003.jpg"></graphic><mml:math id="M3"><mml:mrow><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">Γ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msqrt><mml:mi mathvariant="normal">Γ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(2)</label></disp-formula>
<disp-formula id="pgen.1006915.e004"><alternatives><graphic id="pgen.1006915.e004g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e004.jpg"></graphic><mml:math id="M4"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>q</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mi>u</mml:mi><mml:mo>/</mml:mo><mml:mi>s</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(3)</label></disp-formula>
where <italic>N</italic> is the diploid population size and <italic>Γ</italic> is the gamma function (see Simons et al. [<xref ref-type="bibr" rid="pgen.1006915.ref001">1</xref>] for a similar approximation).</p>
<p>In a finite population, the mean frequency, <inline-formula id="pgen.1006915.e005"><alternatives><graphic id="pgen.1006915.e005g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e005.jpg"></graphic><mml:math id="M5"><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math></alternatives></inline-formula>, therefore depends on assumptions about the population mutation rate (2<italic>Nu</italic>). If the population mutation rate is high, such that 2<italic>Nu</italic>&gt;&gt;1, <inline-formula id="pgen.1006915.e006"><alternatives><graphic id="pgen.1006915.e006g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e006.jpg"></graphic><mml:math id="M6"><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math></alternatives></inline-formula> is approximated by
<disp-formula id="pgen.1006915.e007"><alternatives><graphic id="pgen.1006915.e007g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e007.jpg"></graphic><mml:math id="M7"><mml:mrow><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mo>≈</mml:mo><mml:msqrt><mml:mrow><mml:mi>u</mml:mi><mml:mo>/</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msqrt><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(4)</label></disp-formula>
which is independent of the population size and equal to the equilibrium frequency in an infinite population, i.e., the right hand side of Eq (<xref ref-type="disp-formula" rid="pgen.1006915.e002">1</xref>). The important difference between the two models above is that in a finite population, there is a distribution of frequencies <italic>q</italic> (because of genetic drift), whose variance is given in Eq (<xref ref-type="disp-formula" rid="pgen.1006915.e004">3</xref>), rather than a single value, as in an infinite population.</p>
<p>In contrast, when the finite population has a low population mutation rate (<italic>2Nu</italic>&lt;&lt;1), the mean allele frequency, <inline-formula id="pgen.1006915.e008"><alternatives><graphic id="pgen.1006915.e008g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e008.jpg"></graphic><mml:math id="M8"><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math></alternatives></inline-formula>, is approximated by:
<disp-formula id="pgen.1006915.e009"><alternatives><graphic id="pgen.1006915.e009g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e009.jpg"></graphic><mml:math id="M9"><mml:mrow><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mo>≈</mml:mo><mml:mi>u</mml:mi><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi><mml:mi>N</mml:mi><mml:mo>/</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msqrt><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(5)</label></disp-formula>
which depends on the population size [<xref ref-type="bibr" rid="pgen.1006915.ref003">3</xref>].</p>
<p>We note that Nei [<xref ref-type="bibr" rid="pgen.1006915.ref003">3</xref>] assumed a Wright-Fisher model, in which there is no distinction between census and the effective population sizes. However, when the two differ, it is the effective population size that governs the dynamics of deleterious alleles, so the <italic>N</italic> in the analytical results in fact represents the effective population size. In humans, the mutation rate at each bp is very small (on the order of 10<sup>−8</sup> [<xref ref-type="bibr" rid="pgen.1006915.ref018">18</xref>]) and the effective population size not that large, even recently [<xref ref-type="bibr" rid="pgen.1006915.ref027">27</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref028">28</xref>], so the second approximation should apply when considering each single site independently.</p>
<p>The expectation and variance of the frequency of a fatal, fully recessive allele (i.e., <italic>s</italic> = 1, <italic>h</italic> = 0) are then given by:
<disp-formula id="pgen.1006915.e010"><alternatives><graphic id="pgen.1006915.e010g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e010.jpg"></graphic><mml:math id="M10"><mml:mrow><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mi>u</mml:mi><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:msqrt><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(6)</label></disp-formula>
and
<disp-formula id="pgen.1006915.e011"><alternatives><graphic id="pgen.1006915.e011g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e011.jpg"></graphic><mml:math id="M11"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>q</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mi>u</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>π</mml:mi><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≈</mml:mo><mml:mi>u</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:math></alternatives><label>(7)</label></disp-formula>
This single site model implicitly ignores the existence of compound heterozygosity in modeling the strength of selection acting on an individual site.</p>
</sec>
<sec id="sec006">
<title>Comparing mutation-selection balance models</title>
<p>Although an infinite population size has often been assumed when modeling deleterious allele frequencies (e.g. [<xref ref-type="bibr" rid="pgen.1006915.ref005">5</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref029">29</xref>–<xref ref-type="bibr" rid="pgen.1006915.ref032">32</xref>]), predictions under this assumption can differ markedly from what is expected from models of finite population sizes, assuming plausible parameter values for humans. For example, the long-term estimate of the effective population size from total polymorphism levels is ~20,000 individuals (assuming a mutation rate of 1.2 x 10<sup>−8</sup> per bp per generation [<xref ref-type="bibr" rid="pgen.1006915.ref018">18</xref>] and diversity levels of 0.1% [<xref ref-type="bibr" rid="pgen.1006915.ref033">33</xref>]). In this case and considering a mutation rate of 1.5 x 10<sup>−8</sup> for exons (which have a higher mutation rate than the rest of the genome, because of their base composition [<xref ref-type="bibr" rid="pgen.1006915.ref034">34</xref>]), the average deleterious allele frequency in the model of finite population size is ~23-fold lower than that in the infinite population model (<xref ref-type="fig" rid="pgen.1006915.g001">Fig 1</xref>).</p>
<fig id="pgen.1006915.g001" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006915.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Expected allele frequencies in a population, according to mutation-selection balance models.</title>
<p>The blue bar denotes the expected allele frequency under an infinite population size, the green bar the mean under a finite constant population, and the red bar the mean under a plausible demographic model for European populations; for this last case, the entire distribution across 100,000 simulations is shown in the grey histogram. All models assume <italic>s</italic> = 1 and <italic>h</italic> = 0, i.e., fully recessive, lethal mutations. For the finite constant population size model, we present the mean frequency for a population size of 20,000 (see <xref ref-type="supplementary-material" rid="pgen.1006915.s007">S2A Fig</xref> for other choices). Population allele frequencies (<italic>q</italic>) were transformed to log10(<italic>q</italic>), and those <italic>q</italic> = 0 were set to 10<sup>−7</sup> for visual purposes, but indicated as “0” on the X-axis. The density of the distribution is plotted on a log-scale on the Y-axis. The mutation rate <italic>u</italic> was set to 1.5 x 10<sup>−8</sup> per bp per generation in all models.</p>
</caption>
<graphic xlink:href="pgen.1006915.g001"></graphic>
</fig>
<p>Because the human population size has not been constant and changes in the population size can affect the frequencies of deleterious alleles in the population (e.g. [<xref ref-type="bibr" rid="pgen.1006915.ref002">2</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref035">35</xref>]), we also simulated the population dynamics of disease alleles under a plausible demographic model for European populations based on Tennessen et al. [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>]. The original model assumes a genome-wide mutation rate of 2.36 x 10<sup>−8</sup> per bp per generation, when current, more direct estimates are approximately two-fold smaller [<xref ref-type="bibr" rid="pgen.1006915.ref018">18</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref034">34</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref036">36</xref>]. We therefore rescaled the demographic parameters of the Tennessen et al. model, based on a mutation rate of 1.2 x 10<sup>−8</sup> [<xref ref-type="bibr" rid="pgen.1006915.ref018">18</xref>] (see <xref ref-type="sec" rid="sec009">Methods</xref>). Assuming a mutation rate of 1.5 x 10<sup>−8</sup> per bp (as recently estimated for exons [<xref ref-type="bibr" rid="pgen.1006915.ref034">34</xref>]), the mean allele frequency of a lethal, recessive disease allele obtained from this model was 7.10 x 10<sup>−6</sup>, ~1.33-fold higher than expected for a constant population size model with <italic>N</italic><sub><italic>e</italic></sub> = 20,000 (<xref ref-type="fig" rid="pgen.1006915.g001">Fig 1</xref>). The mean frequency seen in simulations instead matches the expectation for a constant population size of 35,651 individuals (see <xref ref-type="sec" rid="sec009">Methods</xref> and <xref ref-type="supplementary-material" rid="pgen.1006915.s007">S2A Fig</xref>). Increasing the effective population size in a constant size model is not enough to capture the dynamics of disease alleles appropriately, however. For example, if simulation results obtained under the Tennessen et al. [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>] demographic model are compared to those for simulations of a constant population size of <italic>N</italic><sub><italic>e</italic></sub> = 35,651, the mean allele frequencies match, but the distributions of allele frequencies are significantly different (Kolmogorov-Smirnov test, p-value &lt; 10<sup>−15</sup>; <xref ref-type="supplementary-material" rid="pgen.1006915.s007">S2B and S2C Fig</xref>). These findings thus confirm the importance of incorporating demographic history into models for understanding the population dynamics of disease alleles [<xref ref-type="bibr" rid="pgen.1006915.ref005">5</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref037">37</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref038">38</xref>]. In what follows, we therefore tested the fit of the more realistic demographic model [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>] (and variants of it) to the observed allele frequencies.</p>
</sec>
<sec id="sec007">
<title>Comparing empirical and expected distributions of disease allele frequencies</title>
<p>The mutation rate from wild-type allele to disease allele, <italic>u</italic>, is a critical parameter in predicting the frequencies of a deleterious allele [<xref ref-type="bibr" rid="pgen.1006915.ref004">4</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref039">39</xref>]. To model disease alleles, we considered four mutation types separately, with the goal of capturing most of the fine-scale heterogeneity in mutation rates [<xref ref-type="bibr" rid="pgen.1006915.ref027">27</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref036">36</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref040">40</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref041">41</xref>]: transitions in methylated CpG sites (CpGti) and three less mutable types, namely transversions in CpG sites (CpGtv) and transitions and transversions outside a CpG site (nonCpGti and nonCpGtv, respectively). In order to control for the methylation status of CpG sites, we excluded 12 CpGti that occurred in CpG islands, which tend not to be methylated and thus are likely to have a lower mutation rate [<xref ref-type="bibr" rid="pgen.1006915.ref036">36</xref>] (following Moorjani et al. [<xref ref-type="bibr" rid="pgen.1006915.ref042">42</xref>]). To allow for heterogeneity in mutation rates within each one of these four classes considered, we modeled the within-class variation in mutation rates according to a lognormal distribution (see details in <xref ref-type="sec" rid="sec009">Methods</xref> and [<xref ref-type="bibr" rid="pgen.1006915.ref027">27</xref>]).</p>
<p>For each mutation type, we then compared the mean allele frequency obtained from simulations to what is observed in ExAC, running 100,000 replicates. To this end, we matched simulations to the empirical data with regard to the number of individuals sampled and number of mutations observed of each mutation type and focused the analysis on the largest sample of the same common ancestry, namely Non-Finnish Europeans (<italic>n</italic> = 33,370) (<xref ref-type="fig" rid="pgen.1006915.g002">Fig 2A</xref>). We found significant differences between empirical and expected mean frequencies for nonCpGtv (30-fold higher on average; two-tailed p-value &lt; 1 x 10<sup>−4</sup>; see <xref ref-type="sec" rid="sec009">Methods</xref> for details) and nonCpGti (15-fold higher on average, two-tailed p-value &lt; 1 x 10<sup>−4</sup>), but only marginally so for CpGtv (5-fold higher on average, two-tailed p-value = 0.08). The mean frequency for CpGti is also somewhat higher than expected, but insignificantly so (1.17-fold higher on average, two-tailed p-value = 0.59). Intriguingly, the discrepancy between observed and expected frequencies becomes smaller as the mutation rate increases (<xref ref-type="fig" rid="pgen.1006915.g002">Fig 2B</xref>).</p>
<fig id="pgen.1006915.g002" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006915.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Comparison between expected and observed mean allele frequencies of recessive, lethal disease mutations.</title>
<p>(A) Shown are the expected and observed mean sample frequencies of disease mutations for four different mutation types. The title of the panel indicates the mutation type, followed by <italic>K</italic>, the total number of mutations of that type considered in this study, with the p-value for the difference between observed and expected mean frequencies given below. Distributions in grey are the mean sample allele frequencies across <italic>K</italic> mutations based on 100,000 simulations, and rely on a plausible demographic model for European populations [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>] (see <xref ref-type="sec" rid="sec009">Methods</xref>). Blue bars represent the observed mean frequencies of the four mutation types, estimated from 33,370 individuals of European ancestry from ExAC. (B) Fold increase in the observed mean allele frequency in relation to the expected, as a function of the mutation rate <italic>u</italic> (on a log-scale), for each of the four mutation classes.</p>
</caption>
<graphic xlink:href="pgen.1006915.g002"></graphic>
</fig>
<p>Two additional factors that we have not included in our model should further decrease the predicted frequencies of disease alleles. Given that frequencies in ExAC are already unexpectedly high, these factors would only exacerbate the discrepancy between observed and expected frequencies of deleterious alleles. First, we have ignored the effects of compound heterozygosity, the case in which combinations of two distinct pathogenic alleles in the same gene lead to lethality. This phenomenon is known to be common [<xref ref-type="bibr" rid="pgen.1006915.ref043">43</xref>], and indeed, in the 320 cases in which we were able to obtain this information, 58.44% were initially identified in compound heterozygotes. In the presence of compound heterozygosity, each deleterious mutation will be selected against not only when present in two copies within the same individual, but also in the presence of lethal mutations at other sites. Since the purging effect of selection against compound heterozygotes was not modeled in simulations, we would predict the frequency of a deleterious mutation to be even lower than shown (e.g., in <xref ref-type="fig" rid="pgen.1006915.g002">Fig 2A</xref>).</p>
<p>In order to model the effect of compound heterozygosity in our simulations, we re-ran our simulations, but focusing on a gene rather than a single site and so considering the sum of frequencies of all known recessive lethal alleles within a gene. In these simulations, we used the same set-up as in the site level analysis, except for the mutation rate, <italic>U</italic>, which is now the sum of the mutation rates <italic>u</italic><sub><italic>j</italic></sub> at each site <italic>j</italic> that is known to cause a severe and early onset form of the disease [<xref ref-type="bibr" rid="pgen.1006915.ref008">8</xref>] (<xref ref-type="supplementary-material" rid="pgen.1006915.s002">S2 Table</xref>; see <xref ref-type="sec" rid="sec009">Methods</xref> for details). This approach does not consider the contribution of other mutations in the genes that cause the mild and/or late onset forms of the disease, and implicitly assumes that all combinations of known recessive lethal alleles of the same gene have the same fitness effect as homozygotes. Comparing observed frequencies of disease alleles for each gene to predictions generated by simulation, about a fourth of the 27 genes for which we implemented the gene-level analysis (see <xref ref-type="sec" rid="sec009">Methods</xref>) differ from the expected distribution at the 5% level, with a clear overall trend for observed frequencies to be above expectation (<xref ref-type="supplementary-material" rid="pgen.1006915.s004">S4 Table</xref>; <xref ref-type="fig" rid="pgen.1006915.g003">Fig 3</xref>; Fisher’s combined probability test p-value = 6 x 10<sup>−8</sup>).</p>
<fig id="pgen.1006915.g003" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006915.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Sample allele frequencies at the gene level.</title>
<p>The expectation (grey) is based on 1000 simulations, assuming no fitness decrease in heterozygotes, but allowing for compound heterozygosity (see <xref ref-type="sec" rid="sec009">Methods</xref> for details). The sum of allele frequencies of known recessive lethal disease mutations in each gene (purple bars) was obtained from ExAC considering 33,370 European individuals. Genes are ordered according to the two-tailed p-value (<xref ref-type="supplementary-material" rid="pgen.1006915.s004">S4 Table</xref>; see <xref ref-type="sec" rid="sec009">Methods</xref>). Genes are bolded when they differ significantly from expectation (at the 5% level). Violin plots show the distribution of the log<sub>10</sub> combined allele frequency of all segregating alleles obtained from simulations and boxes represent the fraction of simulations in which no deleterious allele was observed in the simulated sample at present time.</p>
</caption>
<graphic xlink:href="pgen.1006915.g003"></graphic>
</fig>
<p>This finding is even more surprising than it may seem, because we are far from knowing the complete mutation target for each gene, i.e., all the sites at which mutations could cause the disease. If there are additional, undiscovered sites in the gene at which mutations are fatal when carried in combination with a known recessive lethal mutation, the purging effect of purifying selection on the known mutations will be under-estimated in our simulations, leading us to over-estimate the expected frequencies of the known mutations in simulations. Therefore, our predictions are, if anything, an over-estimate of the expected allele frequency, and the discrepancy between predicted and the observed is likely even larger than what we found.</p>
<p>The other factor that we did not consider in simulations but would reduce the expected allele frequencies is a subtle fitness decrease in heterozygotes, as has been documented in Drosophila for example [<xref ref-type="bibr" rid="pgen.1006915.ref044">44</xref>]. To evaluate potential fitness effects in heterozygotes when none had been documented in humans, we considered the phenotypic consequences of orthologous gene knockouts in mouse. We were able to retrieve information on phenotypes for both homozygote and heterozygote mice for only eight out of the 32 genes, namely <italic>ASS1</italic>, <italic>CFTR</italic>, <italic>DHCR7</italic>, <italic>NPC1</italic>, <italic>POLG</italic>, <italic>PRF1</italic>, <italic>SLC22A5</italic>, and <italic>SMPD1</italic>. For all eight, homozygote knockout mice presented similar phenotypes as affected humans, and heterozygotes showed a milder but detectable phenotype (<xref ref-type="supplementary-material" rid="pgen.1006915.s005">S5 Table</xref>). The magnitude of the heterozygote effect of these mutations in humans is unclear, but the finding with knockout mice makes it plausible that there exists a very small fitness decrease in heterozygotes in humans as well, potentially not enough to have been recognized in clinical investigations but enough to have a marked impact on the allele frequencies of the disease mutations. Indeed, even if the fitness effect in heterozygotes were as small as <italic>h</italic> = 1%, a 79% decrease in the mean allele frequency of the disease allele is expected relative to the case with complete recessivity (<italic>h</italic> = 0) (<xref ref-type="supplementary-material" rid="pgen.1006915.s008">S3 Fig</xref>).</p>
</sec>
</sec>
<sec id="sec008" sec-type="conclusions">
<title>Discussion</title>
<p>To investigate the population genetics of human disease, we focused on mutations that cause Mendelian, recessive disorders that lead to early death or completely impaired reproduction. We sought to understand to what extent the frequencies of these mutations fit the expectation based on a simple balance between the input of mutations and the purging by purifying selection, as well as how other mechanisms might affect these frequencies. Many studies implicitly or explicitly compare known disease allele frequencies to expectations from mutation-selection balance [<xref ref-type="bibr" rid="pgen.1006915.ref005">5</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref029">29</xref>–<xref ref-type="bibr" rid="pgen.1006915.ref032">32</xref>]. In this study, we tested whether known recessive lethal disease alleles as a class fit these expectations, and found that, under a sensible demographic model for European population history with purifying selection only in homozygotes, the expectations fit the observed disease allele frequencies poorly: the mean empirical frequencies of disease alleles are substantially above expectation for all mutation types (although not significantly so for CpGti), and the fold increase in observed mean allele frequency in relation to the expectation decreases with increased mutation rate (<xref ref-type="fig" rid="pgen.1006915.g002">Fig 2</xref>). Furthermore, including possible effects of compound heterozygosity and subtle fitness decrease in heterozygotes will only exacerbate the discrepancy.</p>
<p>In principle, higher than expected disease allele frequencies could be explained by at least six (non-mutually exclusive) factors: (i) widespread errors in reporting the causal variants; (ii) misspecification of the demographic model, (iii) misspecification of the mutation rate; (iv) reproductive compensation; (v) overdominance of disease alleles; and (vi) low penetrance of disease mutations. Because widespread mis-annotation of the causal variants in disease mutation databases had previously been reported [<xref ref-type="bibr" rid="pgen.1006915.ref023">23</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref045">45</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref046">46</xref>], we tried to minimize the effect of such errors on our analyses by filtering out any case that lacked compelling evidence of association with a recessive lethal disease, reducing our initial set of 769 mutations to 385 in which we had greater confidence (see <xref ref-type="sec" rid="sec009">Methods</xref> for details).</p>
<p>We also explored the effects of having misspecified recent demographic history or the mutation rate. Based on very large samples, it has been estimated that population growth in Europe was stronger than what we considered in our simulations [<xref ref-type="bibr" rid="pgen.1006915.ref047">47</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref048">48</xref>]. When we considered higher growth rates, such that the current effective population size is up to 10-fold larger than that of the rescaled Tennessen model, we observed an increase in the expected frequency of recessive disease alleles and a larger number of segregating sites (<xref ref-type="supplementary-material" rid="pgen.1006915.s009">S4 Fig</xref>, columns A-E). However, the impact of larger growth rate is insufficient to explain the observed discrepancy: the allele frequencies observed in ExAC are still on average an order of magnitude larger than expected based on a model with a 10-fold larger current effective population size than the one initially considered [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>] (<xref ref-type="supplementary-material" rid="pgen.1006915.s009">S4 Fig</xref>). In turn, population substructure within Europe would only increase the number of homozygotes relative to what was modeled in our simulations (through the Wahlund effect [<xref ref-type="bibr" rid="pgen.1006915.ref049">49</xref>]) and expose more recessive alleles to selection, thus decreasing the expected allele frequencies and exacerbating the discrepancy that we report.</p>
<p>To explore the effects of error in the mutation rate, we considered a 50% higher mean mutation rate than what has been estimated for exons [<xref ref-type="bibr" rid="pgen.1006915.ref034">34</xref>], beyond what seems plausible based on current estimates on human mutation rates [<xref ref-type="bibr" rid="pgen.1006915.ref042">42</xref>]. Except for the mean mutation rate (now set to 2.25 x 10<sup>−8</sup>), all other parameters used for these simulations (i.e. the variance in mutation rate across simulations, the demographic model [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>], absence of selective effect in heterozygotes, and selection coefficient) were kept the same as the ones used for generating <xref ref-type="supplementary-material" rid="pgen.1006915.s009">S4 Fig</xref>, column A. The observed mean frequency remains significantly above what those predicted and qualitative conclusions are unchanged (<xref ref-type="supplementary-material" rid="pgen.1006915.s009">S4 Fig</xref>, column F).</p>
<p>Another factor to consider is that for disease phenotypes that are lethal very early on in life, there may be partial or complete reproductive compensation (e.g. [<xref ref-type="bibr" rid="pgen.1006915.ref050">50</xref>]). This phenomenon would decrease the fitness effects of the recessive lethal mutations and could therefore lead to an increase in the allele frequency in data relative to what we predict for a selection coefficient of 1. There are no reasons, however, for this phenomenon to correlate with the mutation rate, as seen in <xref ref-type="fig" rid="pgen.1006915.g002">Fig 2B</xref>.</p>
<p>The other two factors, overdominance and low penetrance, are likely explanations for a subset of cases. For instance, <italic>CFTR</italic>, the gene in which some mutations lead to cystic fibrosis, is the farthest above expectation (p-value &lt; 0.004; <xref ref-type="fig" rid="pgen.1006915.g003">Fig 3</xref>). It was long noted that there is an unusually high frequency of the <italic>CFTR</italic> deletion ΔF508 in Europeans, which led to speculation that disease alleles of this gene may be subject to over-dominance ([<xref ref-type="bibr" rid="pgen.1006915.ref051">51</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref052">52</xref>], but see [<xref ref-type="bibr" rid="pgen.1006915.ref053">53</xref>]). Regardless, it is known that disease mutations in this gene can complement one another [<xref ref-type="bibr" rid="pgen.1006915.ref010">10</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref011">11</xref>] and that modifier loci in other genes also influence their penetrance [<xref ref-type="bibr" rid="pgen.1006915.ref011">11</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref014">14</xref>]. Consistent with variable penetrance, Chen et al. [<xref ref-type="bibr" rid="pgen.1006915.ref024">24</xref>] identified three purportedly healthy individuals carrying two copies of disease mutations in this gene. Similarly, <italic>DHCR7</italic>, the gene associated with the Smith-Lemli-Opitz syndrome, is somewhat above expectation in our analysis (p-value = 0.056; <xref ref-type="fig" rid="pgen.1006915.g003">Fig 3</xref>) and healthy individuals were found to be homozygous carriers of putatively lethal disease alleles in other studies [<xref ref-type="bibr" rid="pgen.1006915.ref024">24</xref>]. These observations make it plausible that, in a subset of cases (particularly for <italic>CFTR</italic>), the high frequency of deleterious mutations associated with recessive, lethal diseases are due to genetic interactions that modify the penetrance of certain recessive disease mutations. It is hard to assess the importance of this phenomenon in driving the general pattern that we observe, but two factors argue against it being a sufficient explanation for our findings at the level of single sites. First, when we removed 130 mutations in <italic>CFTR</italic> and 12 in <italic>DHCR7</italic>, the two genes that were outliers at the gene level (<xref ref-type="fig" rid="pgen.1006915.g003">Fig 3</xref>; <xref ref-type="supplementary-material" rid="pgen.1006915.s004">S4 Table</xref>) and for which there is evidence of incomplete penetrance [<xref ref-type="bibr" rid="pgen.1006915.ref024">24</xref>], the discrepancy between observed and expected allele frequencies is barely impacted (<xref ref-type="supplementary-material" rid="pgen.1006915.s010">S5 Fig</xref>). Moreover, there is no obvious reason why the degree of incomplete penetrance would vary systematically with the mutation rate of a site, as observed (<xref ref-type="fig" rid="pgen.1006915.g002">Fig 2B</xref>).</p>
<p>Instead, it seems plausible that there is an ascertainment bias in disease allele discovery and mutation identification [<xref ref-type="bibr" rid="pgen.1006915.ref052">52</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref054">54</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref055">55</xref>]. Unlike missense or protein-truncating variants, Mendelian disease mutations cannot be annotated based solely on DNA sequences, and their identification requires reliable diagnosis of affected individuals (usually in more than one pedigree) followed by mapping of the underlying gene/mutation. Therefore, those mutations that have been identified to date are likely the ones that are segregating at higher frequencies in the population. Moreover, mutation-selection balance models predict that the frequency of a deleterious mutation should correlate with the mutation rate. Together, these considerations suggest that disease variants of a highly mutable class, such as CpGti, are more likely to have been mapped and that the mean frequency of mapped mutations will tend to be only slightly above all disease mutations in that class. In contrast, less mutable disease mutations are less likely to have been discovered to date, and the mean frequency of the subset of mutations that have been identified may tend to be far above that of all mutations in that class.</p>
<p>To quantify these effects, we modeled the ascertainment of disease mutations both analytically and in simulations. A large proportion of recessive Mendelian disease mutations were identified in inbred populations, likely because inbreeding leads to an excess of homozygotes compared to expected under random mating, increasing the probability that a recessive mutation would be discovered as causing a disease. Therefore, we modeled ascertainment in disease discovery in human populations with a plausible degree of inbreeding (see <xref ref-type="sec" rid="sec009">Methods</xref>). As expected, we found that for a given mutation type, the probability of ascertainment increases with the sample size of the putative disease ascertainment study (<italic>n</italic><sub><italic>a</italic></sub>) and the average inbreeding coefficient of the population under study (<italic>F</italic><sub><italic>a</italic></sub>); in addition, the average allele frequency of mutations that have been identified is always higher than that of all existing mutations, and the discrepancy decreases as the ascertainment probability increases (<xref ref-type="table" rid="pgen.1006915.t001">Table 1</xref>). Furthermore, comparison across different mutation types reveals that a higher mutation rate increases the probability of disease mutations being ascertained (<xref ref-type="table" rid="pgen.1006915.t001">Table 1</xref> and <xref ref-type="supplementary-material" rid="pgen.1006915.s011">S6 Fig</xref>) and decreases the magnitude of bias in the estimated allele frequency relative to the mutation class as a whole (<xref ref-type="table" rid="pgen.1006915.t001">Table 1</xref>). In summary, among all the possible aforementioned explanations for the observed discrepancy between empirical and expected mean allele frequencies, the ascertainment bias hypothesis is the only one that also explains why it is more pronounced for less mutable mutation types (<xref ref-type="fig" rid="pgen.1006915.g002">Fig 2B</xref>).</p>
<table-wrap id="pgen.1006915.t001" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006915.t001</object-id>
<label>Table 1</label>
<caption>
<title>For a given set of parameters <italic>n</italic><sub><italic>a</italic></sub> (the sample size in a putative disease ascertainment study) and <italic>F</italic><sub><italic>a</italic></sub> (the average inbreeding coefficient of the population in which the study is being performed), we report the probability of a recessive, lethal mutation being ascertained, as well as the fold increase in mean allele frequencies of the ascertained cases (<italic>q</italic><sub><italic>a</italic></sub>) in relation to the mean frequencies of all mutations for each mutation type (<italic>q</italic><sub><italic>u</italic></sub>), based on simulations (see <xref ref-type="sec" rid="sec009">Methods</xref> for details).</title>
<p>For a similar result derived from analytical modeling, see <xref ref-type="supplementary-material" rid="pgen.1006915.s011">S6 Fig</xref>. Parameters for this step of the simulation correspond to plausible scenarios for human populations with widespread inbreeding (e.g., <italic>F</italic><sub><italic>a</italic></sub> = 1/16 corresponds to offspring of first-cousin marriage). The last column in the bottom panel shows the fold increase of the mean allele frequency observed in ExAC in relation to simulations based on the Tennessen et al. [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>] demographic model (see <xref ref-type="sec" rid="sec009">Methods</xref>). Mutation rates <italic>u</italic> per bp, per generation were obtained from a large human pedigree study [<xref ref-type="bibr" rid="pgen.1006915.ref018">18</xref>].</p>
</caption>
<alternatives>
<graphic id="pgen.1006915.t001g" xlink:href="pgen.1006915.t001"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Parameter</bold>
</td>
<td align="center" colspan="5" rowspan="1">
<bold>Simulation settings</bold>
</td>
<td align="center" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>
<italic>n</italic>
</bold>
<sub>
<bold>
<italic>a</italic>
</bold>
</sub>
</td>
<td align="center" colspan="1" rowspan="1">10,000</td>
<td align="center" colspan="1" rowspan="1">10,000</td>
<td align="center" colspan="1" rowspan="1">100,000</td>
<td align="center" colspan="1" rowspan="1">100,000</td>
<td align="center" colspan="1" rowspan="1">500,000</td>
<td align="center" colspan="1" rowspan="2">ExAC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>
<italic>F</italic>
</bold>
<sub>
<bold>
<italic>a</italic>
</bold>
</sub>
</td>
<td align="center" colspan="1" rowspan="1">1/16</td>
<td align="center" colspan="1" rowspan="1">1/8</td>
<td align="center" colspan="1" rowspan="1">1/8</td>
<td align="center" colspan="1" rowspan="1">1/6</td>
<td align="center" colspan="1" rowspan="1">1/8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Mutation type (<italic>u</italic>)</bold>
</td>
<td align="center" colspan="6" rowspan="1">
<bold>Probability of a mutation being ascertained</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>CpGti (1.12e-7)</bold>
</td>
<td align="center" colspan="1" rowspan="1">0.0150</td>
<td align="center" colspan="1" rowspan="1">0.0247</td>
<td align="center" colspan="1" rowspan="1">0.0968</td>
<td align="center" colspan="1" rowspan="1">0.1125</td>
<td align="center" colspan="1" rowspan="1">0.1858</td>
<td align="center" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>CpGtv (9.59e-9)</bold>
</td>
<td align="center" colspan="1" rowspan="1">0.0014</td>
<td align="center" colspan="1" rowspan="1">0.0024</td>
<td align="center" colspan="1" rowspan="1">0.0104</td>
<td align="center" colspan="1" rowspan="1">0.0124</td>
<td align="center" colspan="1" rowspan="1">0.0235</td>
<td align="center" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>nonCpGti (6.18e-9)</bold>
</td>
<td align="center" colspan="1" rowspan="1">0.0009</td>
<td align="center" colspan="1" rowspan="1">0.0015</td>
<td align="center" colspan="1" rowspan="1">0.0067</td>
<td align="center" colspan="1" rowspan="1">0.0074</td>
<td align="center" colspan="1" rowspan="1">0.0146</td>
<td align="center" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>nonCpGtv (3.76e-9)</bold>
</td>
<td align="center" colspan="1" rowspan="1">0.0005</td>
<td align="center" colspan="1" rowspan="1">0.0010</td>
<td align="center" colspan="1" rowspan="1">0.0044</td>
<td align="center" colspan="1" rowspan="1">0.0050</td>
<td align="center" colspan="1" rowspan="1">0.0091</td>
<td align="center" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="center" colspan="6" rowspan="1">
<bold>Fold increase in allele frequency due to ascertainment bias</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>CpGti (1.12e-7)</bold>
</td>
<td align="center" colspan="1" rowspan="1">27.6</td>
<td align="center" colspan="1" rowspan="1">22.3</td>
<td align="center" colspan="1" rowspan="1">9.0</td>
<td align="center" colspan="1" rowspan="1">8.0</td>
<td align="center" colspan="1" rowspan="1">5.2</td>
<td align="center" colspan="1" rowspan="1">1.17</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>CpGtv (9.59e-9)</bold>
</td>
<td align="center" colspan="1" rowspan="1">284.1</td>
<td align="center" colspan="1" rowspan="1">222.6</td>
<td align="center" colspan="1" rowspan="1">81.2</td>
<td align="center" colspan="1" rowspan="1">70.2</td>
<td align="center" colspan="1" rowspan="1">40.6</td>
<td align="center" colspan="1" rowspan="1">5.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>nonCpGti (6.18e-9)</bold>
</td>
<td align="center" colspan="1" rowspan="1">455.7</td>
<td align="center" colspan="1" rowspan="1">335.6</td>
<td align="center" colspan="1" rowspan="1">126.1</td>
<td align="center" colspan="1" rowspan="1">114.8</td>
<td align="center" colspan="1" rowspan="1">64.7</td>
<td align="center" colspan="1" rowspan="1">15.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>nonCpGtv (3.76e-9)</bold>
</td>
<td align="center" colspan="1" rowspan="1">716.5</td>
<td align="center" colspan="1" rowspan="1">577.4</td>
<td align="center" colspan="1" rowspan="1">192.9</td>
<td align="center" colspan="1" rowspan="1">174.1</td>
<td align="center" colspan="1" rowspan="1">103.6</td>
<td align="center" colspan="1" rowspan="1">30.0</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>One implication of this hypothesis is that there are numerous sites at which mutations cause recessive lethal diseases yet to be discovered, particularly at non-CpG sites. More generally, this ascertainment bias complicates the interpretation of observed allele frequencies in terms of the selection pressures acting on disease alleles. Beyond this specific point, our study illustrates how the large sample sizes now made available to researchers in the context of projects like ExAC [<xref ref-type="bibr" rid="pgen.1006915.ref023">23</xref>] can be used not only for direct discovery of disease variants, but also to test why disease alleles are segregating in the population and to understand at what frequencies we might expect to find them in the future.</p>
</sec>
<sec id="sec009" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec010">
<title>Disease allele set</title>
<p>In order to identify single nucleotide variants within the 42 genes associated with lethal, recessive Mendelian diseases (<xref ref-type="supplementary-material" rid="pgen.1006915.s001">S1 Table</xref>), we initially relied on the ClinVar dataset [<xref ref-type="bibr" rid="pgen.1006915.ref056">56</xref>] (accessed on June 3<sup>rd</sup>, 2015). We filtered out any variant that is an indel or a more complex copy number variant or that is ever classified as benign or likely benign in ClinVar (whether or not it is also classified as pathogenic or likely pathogenic). By this approach, we obtained 769 SNVs described as pathogenic or likely pathogenic. For each one of these variants, we searched the literature for evidence that it is exclusively associated to the lethal and early onset form of the disease and was never reported as causing the mild and/or late-onset form of the disease. We considered effects in the absence of medical treatment, as we were interested in the selection pressures acting on the alleles over evolutionary time scales rather than in the last one or two generations, i.e., the period over which treatment became available for some of diseases considered. To evaluate the impact of treatment, we decreased <italic>s</italic> from 1 to 0 (i.e., we assumed a complete absence of selective effects due to treatment) in the last three generations and compared the mean allele frequencies across 100,000 simulations implemented with or without this readjustment in selection coefficient. Because of the stochastic nature of the simulations, we repeated this pairwise comparison 10 times in order to get a range of expected increase in allele frequencies. We observed only a minor increase in the mean allele frequency (2.6% at most) across the 10 replicates. This simulation procedure corresponds to a scenario in which there is an extremely effective treatment for all diseases for the past three generations, which is an overestimate of the effect and length of treatment for the disease set considered.</p>
<p>Variants with mention of incomplete penetrance (i.e. for which homozygotes were not always affected) or with known effects in heterozygote carriers were removed from the analysis. This process yielded 417 SNVs in 32 genes associated with distinct Mendelian recessive lethal disorders (<xref ref-type="supplementary-material" rid="pgen.1006915.s002">S2 Table</xref>). Although these mutations were purportedly associated with completely recessive diseases, we sought to examine whether there would be possible, unreported effects in heterozygous carriers. To this end, we used the Mouse Genome Database (MGD) [<xref ref-type="bibr" rid="pgen.1006915.ref057">57</xref>] (accessed July 29<sup>th</sup>, 2015) and were able to retrieve information for both homozygote and heterozygote mice for eight out of the 32 genes (all of which with a homologue in mice) (<xref ref-type="supplementary-material" rid="pgen.1006915.s005">S5 Table</xref>).</p>
<p>In addition to the information provided by ClinVar for each one of these variants, we considered the immediate sequence context of each SNV, to tailor the mutation rate estimate accordingly [<xref ref-type="bibr" rid="pgen.1006915.ref018">18</xref>]. To do so, we used an in-house Python script and the human genome reference sequence hg19 from UCSC (&lt;<ext-link ext-link-type="uri" xlink:href="http://hgdownload.soe.ucsc.edu/goldenPath/hg19/chromosomes/">http://hgdownload.soe.ucsc.edu/goldenPath/hg19/chromosomes/</ext-link>&gt;).</p>
</sec>
<sec id="sec011">
<title>Genetic datasets</title>
<p>The Exome Aggregation Consortium (ExAC) [<xref ref-type="bibr" rid="pgen.1006915.ref023">23</xref>] was accessed on August 9<sup>th</sup>, 2016. The data consist of genotype frequencies for 60,706 individuals, assigned after Principal Component Analysis to one of seven population labels: African (n = 5,203), East Asian (n = 4,327), Finnish (n = 3,307), Latino (n = 5,789), Non-Finnish European (n = 33,370), South Asian (n = 8,256) and “other” (n = 454) [<xref ref-type="bibr" rid="pgen.1006915.ref023">23</xref>]. We focused our analyses on those individuals of Non-Finnish European descent, because they constitute the largest sample size from a single ancestry group. We note that, some diseases mutations, for instance, those in <italic>ASPA</italic>, <italic>HEXA</italic> and <italic>SMPD1</italic>, are known to be especially prevalent in Ashkenazi Jewish populations, which could potentially bias our results if Ashkenazi Jewish individuals constituted a great portion of the sample we considered. However, this sample includes only ~2,000 (~6%) Ashkenazi individuals (Dr. Daniel MacArthur, personal communication).</p>
<p>From the initial 417 mutations, we filtered out three that were homozygous in at least one individual in ExAC and 29 that had lower coverage, i.e., fewer than 80% of the individuals were sequenced to at least 15x. This approach left us with a set of 385 mutations with a minimum coverage of 27x per sample and an average coverage of 69x per sample (<xref ref-type="supplementary-material" rid="pgen.1006915.s002">S2 Table</xref>). For 248 sites with non-zero sample frequencies, ExAC reported the number of non-Finnish European individuals that were sequenced, which was on average 32,881 individuals [<xref ref-type="bibr" rid="pgen.1006915.ref023">23</xref>]. For the remaining 137 sites, we did not have this information. Nonetheless, the coverage across all samples is reported and does not differ significantly between the two sets of sites (by a Kolmogorov-Smirnov test, p-value = 0.90; <xref ref-type="supplementary-material" rid="pgen.1006915.s012">S7 Fig</xref>). We therefore assumed that mean number of individuals covered for all sites was 32,881 and used this number to obtain sample frequencies from simulations, as explained below.</p>
<p>A second genetic dataset was obtained from Counsyl (&lt;<ext-link ext-link-type="uri" xlink:href="https://www.counsyl.com/">https://www.counsyl.com/</ext-link>&gt;). Counsyl is a commercial genetic screening laboratory that offers, among other products, the “Family Prep Screen”, a genetic screening test intended to detect carrier status for up to 110 recessive Mendelian diseases in couples that are planning to have a child [<xref ref-type="bibr" rid="pgen.1006915.ref020">20</xref>]. A subset of 294,000 of its customers was surveyed by genotyping or sequencing for “routine carrier screening”. This subset excludes individuals with indications for testing because of known personal or family history of Mendelian diseases, infertility, and consanguinity. It therefore represents a more random (with regard to the presence of disease alleles), population-based survey. For these individuals, we had details on self-reported ancestry (14 distinct ethnic/ancestry/geographic groups) and the allele frequencies for 98 mutations that match those that passed our variant selection criteria described above, of which 91 are also sequenced to high coverage in the ExAC database (<xref ref-type="supplementary-material" rid="pgen.1006915.s002">S2 Table</xref>). We focused our analysis of this dataset on the 76,314 individuals of self-reported Northern or Southern European ancestry.</p>
</sec>
<sec id="sec012">
<title>Simulating the evolution of disease alleles with population size change</title>
<p>We modeled the frequency of a deleterious allele in human populations by forward simulations based on a crude but plausible demographic model for human populations from Africa and Europe, inferred from exome data for African-Americans and European-Americans [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>]. To this end, we used a program described in [<xref ref-type="bibr" rid="pgen.1006915.ref001">1</xref>]. In brief, the demographic scenario consists of an Out-of-Africa demographic model, with changes in population size throughout the population history, including a severe bottleneck in Europeans following the split from the African population and a rapid, recent population growth in both populations [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>]. As in Simons et al. [<xref ref-type="bibr" rid="pgen.1006915.ref001">1</xref>], we simulated genetic drift and two-way gene flow between Africans and Europeans in recent history.</p>
<p>The original demographic model was inferred using a mutation rate <italic>u</italic> of 2.36 x 10<sup>−8</sup> per bp per generation [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref058">58</xref>]. More recent estimates, based on direct resequencing of human pedigrees, instead point to mutation rates about 50% smaller than that [<xref ref-type="bibr" rid="pgen.1006915.ref018">18</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref034">34</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref036">36</xref>]. To incorporate what is believed to be a more accurate mutation rate estimate, we rescaled all demographic and time parameters in the original Tennessen et al. [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>] model by a factor of 1.97, based on the difference between the mutation rate considered in the original study and that of Kong et al. [<xref ref-type="bibr" rid="pgen.1006915.ref018">18</xref>] (which is similar to that found in other studies [<xref ref-type="bibr" rid="pgen.1006915.ref048">48</xref>]). We refer to this model as the rescaled Tennessen model and rely on it throughout.</p>
<p>Negative selection acting on a single bi-allelic site was modeled as in the analytic models. Allele frequencies follow a Wright-Fisher sampling scheme in each generation according to these viabilities, with migration rate and population sizes varying according to the demographic scenario considered. Whenever a demographic event (e.g., growth) altered the number of individuals and the resulting number was not an integer, we rounded it to the nearest integer, as in Simons et al. [<xref ref-type="bibr" rid="pgen.1006915.ref001">1</xref>]. A burn-in period of 10<italic>Ne</italic> generations with constant population size <italic>Ne</italic> = 14,328 individuals was implemented in order to ensure an equilibrium distribution of segregating alleles at the onset of demographic changes in Africa, 11,643 generations ago.</p>
<p>In contrast to Simons et al. [<xref ref-type="bibr" rid="pgen.1006915.ref001">1</xref>], our simulations always start with the ancestral allele A fixed and mutation occurs exclusively from this allele to the deleterious one (a), i.e., a mutation occurs with mean probability <italic>u</italic> per gamete, per generation, and there is no back-mutation. However, recurrent mutations at a site are allowed, as in Simons et al. [<xref ref-type="bibr" rid="pgen.1006915.ref001">1</xref>].</p>
<p>When implementing the simulations, we considered a mean mutation rate <italic>u</italic> of 1.5x10<sup>-8</sup> per bp, per generation, as has been estimated for exons [<xref ref-type="bibr" rid="pgen.1006915.ref034">34</xref>], as well as mutation rates for four distinct mutation types (CpGti = 1.12 x 10<sup>−7</sup>; CpGtv = 9.59 x 10<sup>−9</sup>; nonCpGti = 6.18 x 10<sup>−9</sup>; and nonCpGtv = 3.76 x 10<sup>−9</sup>) estimated from a large human pedigree study [<xref ref-type="bibr" rid="pgen.1006915.ref018">18</xref>]. While these four categories capture much of the variation in germline mutation rates across sites, a number of other factors (e.g., the larger sequence context or the replication timing) also influence mutation rates, introducing heterogeneity in the mutation rate within each class considered [<xref ref-type="bibr" rid="pgen.1006915.ref027">27</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref036">36</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref040">40</xref>,<xref ref-type="bibr" rid="pgen.1006915.ref059">59</xref>]. To allow for this heterogeneity as well as for uncertainty in the point mutation rates estimates, in each simulation, when compared to human exome data (Figs <xref ref-type="fig" rid="pgen.1006915.g001">1</xref>, <xref ref-type="fig" rid="pgen.1006915.g002">2</xref>, <xref ref-type="supplementary-material" rid="pgen.1006915.s009">S4</xref> and <xref ref-type="supplementary-material" rid="pgen.1006915.s010">S5</xref>), instead of using a fixed rate <italic>u</italic>, we drew the mutation rate <italic>M</italic> from a lognormal distribution with the following parameters:
<disp-formula id="pgen.1006915.e012"><alternatives><graphic id="pgen.1006915.e012g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e012.jpg"></graphic><mml:math id="M12"><mml:mrow><mml:msub><mml:mi mathvariant="normal">log</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mi>M</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mi>u</mml:mi><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>log</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mi>u</mml:mi><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mi mathvariant="normal">ln</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>10</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives><label>(8)</label></disp-formula>
such that that <italic>E</italic>[<italic>M</italic>] = <italic>u</italic>. σ was set to 0.57 (following [<xref ref-type="bibr" rid="pgen.1006915.ref027">27</xref>]).</p>
<p>For each mutation type, we then proceeded as follows:</p>
<list list-type="order">
<list-item>
<p>We ran two million simulations, thus obtaining the distribution of deleterious allele frequencies expected for the European population.</p>
</list-item>
<list-item>
<p>We sampled <italic>K</italic> allele frequencies from the two million simulations implemented for each mutation type, where <italic>K is</italic> the number of identified mutations of that type. Sample allele frequencies were simulated from these population frequencies by Poisson sampling, so to match ExAC’s number of chromosomes.</p>
</list-item>
<list-item>
<p>We repeated step (2) 100,000 times, thus obtaining a distribution for the mean allele frequency across <italic>K</italic> mutations.</p>
</list-item>
</list>
<p>To assess the significance of the deviation between observed and expected mean, we obtained a two-tailed p-value, defined as 2 x (<italic>r</italic>+1)/(100000+1), where <italic>r</italic> is the number of simulated allele frequencies that were greater or equal to that of the empirical mean [<xref ref-type="bibr" rid="pgen.1006915.ref060">60</xref>], for each mutation type separately.</p>
<p>A well-known source of heterogeneity in mutation rate within the CpGti class is methylation status, with a high transition rate seen only at methylated CpGs [<xref ref-type="bibr" rid="pgen.1006915.ref021">21</xref>]. In our analyses, we tried to control for the methylation status of CpG sites by excluding sites located in CpG islands (CGIs), which tend to not be methylated [<xref ref-type="bibr" rid="pgen.1006915.ref042">42</xref>]. The CGI annotation for hg19 was obtained from UCSC Genome Browser (track “Unmasked CpG”; &lt;<ext-link ext-link-type="uri" xlink:href="http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/cpgIslandExtUnmasked.txt.gz">http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/cpgIslandExtUnmasked.txt.gz</ext-link>&gt;, accessed in June 6th, 2016). BEDTools [<xref ref-type="bibr" rid="pgen.1006915.ref061">61</xref>] was used to exclude those CpG sites located in CGIs. We note that the CpGti estimate from [<xref ref-type="bibr" rid="pgen.1006915.ref018">18</xref>] includes CGIs, and in that sense the average mutation rate that we are using for CpGti may be a very slight underestimate of the mean rate for transitions at methylated CpG sites.</p>
<p>Unless otherwise noted, the expectation assumes fully recessive, lethal alleles with complete penetrance. Notably, by calculating the expected frequency one site at a time, we are ignoring possible interaction between genes (i.e., effects of the genetic background) and among different mutations within a gene (i.e., compound heterozygotes). These assumptions are relaxed in two ways. In one analysis (<xref ref-type="supplementary-material" rid="pgen.1006915.s008">S3 Fig</xref>), we considered a very low selective effect in heterozygous individuals (<italic>h</italic> = 1%), reasoning that such an effect could plausibly go undetected in medical examinations and yet would nonetheless impact the frequency of the disease allele. Second, when considering the gene-level analysis (<xref ref-type="fig" rid="pgen.1006915.g003">Fig 3</xref>), we implicitly allowed for compound heterozygosity between any pair of known lethal mutations [<xref ref-type="bibr" rid="pgen.1006915.ref008">8</xref>]. For this analysis, we ran 1000 simulations for a total mutation rate <italic>U</italic> per gene that was calculated accounting for the heterogeneity and uncertainty in the mutation rates estimates as follows: (i) For <italic>j</italic> sites in a gene known to cause a recessive lethal disease and that passed our filtering criteria (<xref ref-type="supplementary-material" rid="pgen.1006915.s002">S2 Table</xref>), we drew a mutation rate <italic>u</italic><sub><italic>j</italic></sub> from the lognormal distribution, as described above; (ii) We then took the sum of <italic>u</italic><sub><italic>j</italic></sub> as the total mutation rate <italic>U;</italic> (iii) We then ran one replicate with <italic>U</italic> as the mutation parameter, and other parameters as specified for site level analysis. Because the mutational target size considered in simulations is only comprised of those sites at which mutations are known to cause a lethal recessive disease, it is almost certainly an underestimate of the true mutation rate—potentially by a lot. We note further that by this approach, we are assuming that compound heterozygotes formed by any two lethal alleles have fitness zero, i.e., that they are identical in their effects to homozygotes for any of the lethal alleles. Moreover, we are implicitly ignoring the possibility of complementation, which is (somewhat) justified by our focus on mutations with severe effects and complete penetrance (but see <xref ref-type="sec" rid="sec008">Discussion</xref>). Since we were interested in understanding the effect of compound heterozygosity, for this analysis, we did not consider the five genes in which only one mutation passed our filters (<italic>BCS1L</italic>, <italic>FKTN</italic>, <italic>LAMA3</italic>, <italic>PLA3G6</italic>, and <italic>TCIRG1</italic>).</p>
</sec>
<sec id="sec013">
<title>Modeling the effect of the ascertainment bias in disease discovery</title>
<p>To calculate the probability of ascertaining a recessive, lethal mutation, we assumed that all currently known disease mutations were identified in a putative ascertainment study of sample size <italic>n</italic><sub><italic>a</italic></sub> in a population with an inbreeding coefficient of <italic>F</italic><sub><italic>a</italic></sub>. Under this model, we can estimate <italic>P</italic><sub><italic>asc</italic></sub>, the probability of ascertaining a disease mutation, as following:</p>
<p>For a disease allele (denoted as <italic>a</italic>) at frequency <italic>q</italic> in the present population, if we randomly sample an individual with inbreeding coefficient of <italic>F<sub>a</sub></italic>, the probabilities of the three genotypes are:
<disp-formula id="pgen.1006915.e013"><alternatives><graphic id="pgen.1006915.e013g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e013.jpg"></graphic><mml:math id="M13"><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>q</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>q</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:math></alternatives><label>(9)</label></disp-formula>
<disp-formula id="pgen.1006915.e014"><alternatives><graphic id="pgen.1006915.e014g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e014.jpg"></graphic><mml:math id="M14"><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>q</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math></alternatives><label>(10)</label></disp-formula>
<disp-formula id="pgen.1006915.e015"><alternatives><graphic id="pgen.1006915.e015g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e015.jpg"></graphic><mml:math id="M15"><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mi>a</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mi>q</mml:mi><mml:mo>+</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo><mml:msup><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>.</mml:mo></mml:math></alternatives><label>(11)</label></disp-formula></p>
<p>Thus, if <italic>n</italic><sub><italic>a</italic></sub> unrelated individual are surveyed, the probability of not seeing any homozygote for the disease allele (which is the same as the probability of not being ascertained in this set) is:
<disp-formula id="pgen.1006915.e016"><alternatives><graphic id="pgen.1006915.e016g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e016.jpg"></graphic><mml:math id="M16"><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mi>a</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup><mml:mo>.</mml:mo></mml:math></alternatives><label>(12)</label></disp-formula>
Therefore, the probability of ascertainment is
<disp-formula id="pgen.1006915.e017"><alternatives><graphic id="pgen.1006915.e017g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pgen.1006915.e017.jpg"></graphic><mml:math id="M17"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mspace width="3em"></mml:mspace><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="5em"></mml:mspace><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mi>q</mml:mi><mml:mo>−</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>)</mml:mo><mml:msup><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>q</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>q</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mi>q</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(13)</label></disp-formula>
which is an increasing function with regard to <italic>q</italic> (the population allele frequency), <italic>F</italic><sub><italic>a</italic></sub> (the inbreeding coefficient of the population under study) as well as <italic>n</italic><sub><italic>a</italic></sub> (the sample size of the putative ascertainment study) (<xref ref-type="supplementary-material" rid="pgen.1006915.s011">S6 Fig</xref>).</p>
<p>We also demonstrate the relationship between the probability of ascertainment and mutation rate using simulations of ascertainment bias implemented according to the following steps:</p>
<list list-type="order">
<list-item>
<p>For each of the four mutation types considered, we generated 10<sup>6</sup> allele frequencies <italic>q</italic> from the results of the simulations based on a realistic demographic model [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>].</p>
</list-item>
<list-item>
<p>We generated <italic>n</italic><sub><italic>a</italic></sub> independent diploid genotypes, given the allele frequencies from step 1 and an inbreeding coefficient <italic>F</italic><sub><italic>a</italic></sub>. We ran this step for a range of <italic>n</italic><sub><italic>a</italic></sub> and <italic>F</italic><sub><italic>a</italic></sub> values (<xref ref-type="table" rid="pgen.1006915.t001">Table 1</xref>).</p>
</list-item>
<list-item>
<p>With a given combination of <italic>n</italic><sub><italic>a</italic></sub> and <italic>F</italic><sub><italic>a</italic></sub> values, we identified the cases (out of the 10<sup>6</sup> observations from step 1) where at least one homozygote individual was observed in step 2. These cases correspond to disease mutations that were ascertained; the reasoning being that given complete penetrance, a recessive disease mutation can only be identified if there is at least one affected individual in the studied population. With this step, we calculated the probability of ascertainment by taking the fraction of cases that satisfy the criteria above.</p>
</list-item>
<list-item>
<p>Finally, for each one of the 10<sup>6</sup> simulations from step 1, we generated a sample allele frequency of the disease mutation, matching ExAC’s sample size (i.e., considering 2n = 65,762 chromosomes). We can then compare <italic>q</italic><sub><italic>u</italic></sub>, the unbiased average allele frequency of all disease mutations, to <italic>q</italic><sub><italic>a</italic></sub>, the mean frequency of the subset of cases ascertained in step 3, i.e., those cases for which at least one homozygote individual is observed.</p>
</list-item>
</list>
<p>These simulations were meant to illustrate the likely impact of ascertainment bias, rather than to precisely describe the disease mutation identification process or to quantify the expected effect. Notably, we performed these simulations for single sites, so the criteria for ascertainment in step 3 did not include the possibility of compound heterozygotes, despite the fact that an estimated 58.4% of the disease mutations included in our study were initially identified in compound heterozygotes. However, this simulation framework could readily be extended in this direction and it would not change our qualitative conclusion.</p>
</sec>
</sec>
<sec id="sec014" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="pgen.1006915.s001">
<label>S1 Table</label>
<caption>
<title>List of lethal, recessive Mendelian diseases considered in this study.</title>
<p>(DOCX)</p>
</caption>
<media xlink:href="pgen.1006915.s001.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pgen.1006915.s002">
<label>S2 Table</label>
<caption>
<title>Information on 417 mutations associated with the severe form of lethal, recessive Mendelian diseases.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pgen.1006915.s002.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pgen.1006915.s003">
<label>S3 Table</label>
<caption>
<title>Information on 91 mutations associated with the severe form of lethal, recessive Mendelian diseases in Counsyl and ExAC databases.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pgen.1006915.s003.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pgen.1006915.s004">
<label>S4 Table</label>
<caption>
<title>P-values for each gene estimated by simulation, under a model of mutation-selection balance with a plausible demographic history.</title>
<p>(DOCX)</p>
</caption>
<media xlink:href="pgen.1006915.s004.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pgen.1006915.s005">
<label>S5 Table</label>
<caption>
<title>Phenotypic effect of mouse knock-outs (see main text).</title>
<p>(DOCX)</p>
</caption>
<media xlink:href="pgen.1006915.s005.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pgen.1006915.s006">
<label>S1 Fig</label>
<caption>
<title>Comparison of the empirical allele frequencies of recessive, lethal disease mutations in individuals of European ancestry from two large exome studies.</title>
<p>Shown are the allele frequencies for 91 variants associated with lethal, recessive diseases, as estimated from 33,370 individuals of non-Finnish, European ancestry in the Exome Aggregation Consortium (ExAC) database [<xref ref-type="bibr" rid="pgen.1006915.ref023">23</xref>] and 76,314 European-ancestry individuals from a genetic testing laboratory (Counsyl [<xref ref-type="bibr" rid="pgen.1006915.ref020">20</xref>]) (see <xref ref-type="sec" rid="sec009">Methods</xref>). Points lie on the dashed blue line if the allele frequencies in Counsyl and ExAC are the same.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pgen.1006915.s006.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pgen.1006915.s007">
<label>S2 Fig</label>
<caption>
<title>Comparisons of mutation-selection balance models with constant versus changing population sizes.</title>
<p>(A) Population mean allele frequency as a function of effective population size, under a model of constant population size. The X-axis range corresponds to the range of effective population size over time estimated in [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>]. The red bar indicates the value of a constant population size at which the mean allele frequency is the same as in simulations, for an average mutation rate of 1.5 x10<sup>-8</sup> per bp per generation [<xref ref-type="bibr" rid="pgen.1006915.ref034">34</xref>]. (B-C) The allele frequency distribution (in grey) is presented for 2 x 10<sup>6</sup> simulations based on (B) the complex demographic scenario inferred by Tennessen et al. [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>] for the evolution of European populations based on simulations (see <xref ref-type="sec" rid="sec009">Methods</xref>) and of (C) the finite, constant size population model, with <italic>N</italic> set to 35,651 individuals to match the mean allele frequency with (B). Both models assume complete lethality (<italic>s</italic> = 1) and recessivity (<italic>h</italic> = 0).</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pgen.1006915.s007.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pgen.1006915.s008">
<label>S3 Fig</label>
<caption>
<title>The impact on disease allele frequencies of a small fitness effect in heterozygotes (<italic>h</italic> = 0.01).</title>
<p>Shown in each case is the distribution of the deleterious allele frequencies in the population, generated from 100,000 simulations. Means are represented by red vertical bars. For visualization, an allele frequency of <italic>q</italic> = 0 is set to 0.5 x 10<sup>−6</sup>. When a small fitness effect in heterozygotes is considered in the simulations, the mean allele frequency decreases by 79% relative to no effect. The two distributions differ significantly by a Kolmogorov-Smirnov test (p-value &lt; 10<sup>−15</sup>). The mutation rate <italic>u</italic> was set to 1.5 x 10<sup>−8</sup> per bp per generation, reflective of the mean mutation rate for exons [<xref ref-type="bibr" rid="pgen.1006915.ref034">34</xref>].</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pgen.1006915.s008.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pgen.1006915.s009">
<label>S4 Fig</label>
<caption>
<title>Effect of varying the end population size and the average mutation rate on the sample allele frequency of recessive, lethal mutations.</title>
<p>Tennessen et al. [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>] inferred the present effective population size of Europeans to be 512,000 individuals based on a mutation rate of 2.36 x 10<sup>−8</sup> per bp per generation. We rescaled the parameters of this model based on a lower mutation rate estimate of 1.2 x 10<sup>−8</sup> [<xref ref-type="bibr" rid="pgen.1006915.ref018">18</xref>] and show the expected distribution of sample allele frequencies of recessive, lethal mutations in column A. We further considered the effect of larger population sizes at present (2-, 4-, and 10-fold increase, denoted by columns B, C and D respectively), keeping other rescaled demographic parameters the same as in A. We also included a model (E) where rapid growth begins immediately after the out-of-Africa bottleneck, representing a more extreme scenario of population growth in comparison to the two-stage and more gradual scenario proposed by Tennessen et al. (2012). For A-E, we drew the mutation rate <italic>M</italic> from a lognormal distribution with parameters set as in <xref ref-type="disp-formula" rid="pgen.1006915.e012">Eq 8</xref>, with <italic>u</italic> = 1.5 x 10<sup>-8</sup> (as implemented for <xref ref-type="fig" rid="pgen.1006915.g002">Fig 2</xref>; see <xref ref-type="sec" rid="sec009">Methods</xref>). Model F considers a larger <italic>u</italic> (2.25 x 10<sup>−8</sup>, i.e., a 1.5-fold increase from A-E), with all other parameters (e.g., variance in mutation rates across simulations, the demographic model) the same as in column A. The observed sample allele frequency distribution of 385 disease mutations in ExAC is shown in white. Violin plots show the density distribution of the log<sub>10</sub> allele frequencies for variants that were segregating in these samples, whereas boxes indicate the proportion of sites for which the deleterious mutation was not observed segregating in the sample. All distributions differ significantly from one another (i.e., all p-values are &lt; 10<sup>−15</sup> by a Kolmogorov-Smirnov test).</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pgen.1006915.s009.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pgen.1006915.s010">
<label>S5 Fig</label>
<caption>
<title>Expected distribution and the observed mean allele frequencies of recessive, lethal disease mutations (excluding mutations in <italic>CFTR</italic> and <italic>DHCR7</italic>).</title>
<p>As in <xref ref-type="fig" rid="pgen.1006915.g002">Fig 2</xref>, the four panels correspond to four different mutation types. The title of the panel indicates the mutation type, followed by <italic>K</italic>, the total number of mutations of that type, with p-values for the difference between observed and expected mean frequencies below. Distributions in grey are for 100,000 observations of the expected mean sample allele frequencies across <italic>K</italic> mutations, and were obtained from simulations based on a plausible demographic model for European populations [<xref ref-type="bibr" rid="pgen.1006915.ref025">25</xref>] (see <xref ref-type="sec" rid="sec009">Methods</xref>). Blue bars represent the observed values estimated from 33,370 individuals of European ancestry from ExAC. As opposed to in <xref ref-type="fig" rid="pgen.1006915.g002">Fig 2</xref>, here, we did not include mutations present in two genes (<italic>CFTR</italic> and <italic>DHCR7</italic>) that were outliers in the gene-level analysis (<xref ref-type="fig" rid="pgen.1006915.g003">Fig 3</xref>) and were reported elsewhere to be carried by healthy homozygous individuals [<xref ref-type="bibr" rid="pgen.1006915.ref024">24</xref>].</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pgen.1006915.s010.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pgen.1006915.s011">
<label>S6 Fig</label>
<caption>
<title>The probability <italic>P</italic><sub><italic>asc</italic></sub> of a mutation being ascertained, given its population allele frequency <italic>q</italic>, the sample size <italic>n</italic><sub><italic>a</italic></sub> of the putative ascertainment study and the inbreeding coefficient <italic>F</italic><sub><italic>a</italic></sub> in the population in which the ascertainment study was conducted.</title>
<p>In each case, we let only one parameter (<italic>q</italic>, <italic>n</italic><sub><italic>a</italic></sub> or <italic>F</italic><sub><bold><italic>a</italic></bold></sub><italic>)</italic> vary, while fixing the others at <italic>q</italic> = 7.10 x 10<sup>−6</sup> (corresponding to the mean allele frequency from simulations), <italic>n</italic><sub><italic>a</italic></sub> = 10,000, and <italic>F</italic><sub><bold><italic>a</italic></bold></sub> = 1/16 (corresponding to marriage between first cousins, a plausible scenario for a population with widespread inbreeding).</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pgen.1006915.s011.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pgen.1006915.s012">
<label>S7 Fig</label>
<caption>
<title>Depth of coverage for 385 mutations in ExAC known to cause lethal, Mendelian diseases.</title>
<p>Box plots show the mean (black bar) and the lower and upper quartiles for (A) the 248 sites with non-zero sample frequencies in ExAC, for which the number of sequenced non-Finnish European individuals was reported (<italic>n</italic> = 32,881) and (B) the 137 sites for which we did not have this information. Since distributions of depth of coverage are similar between the two sets (by a Kolmogorov–Smirnov test, p-value = 0.90), we assumed that 32,881 individuals were sequenced at all sites, and used this number to subsample simulations to match the sample size of the ExAC data.</p>
<p>(TIF)</p>
</caption>
<media xlink:href="pgen.1006915.s012.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We thank Daniel MacArthur for his help with the ExAC data, Ellen Leffler for providing her Python script (available at <ext-link ext-link-type="uri" xlink:href="https://github.com/cegamorim/PopGenHumDisease">https://github.com/cegamorim/PopGenHumDisease</ext-link>), as well as members of the Pickrell, Przeworski and Sella labs, Aravinda Chakravarti, Brian Charlesworth, Damien Labuda and four anonymous reviewers for helpful discussions and comments on an earlier version of the manuscript. All codes and data to generate the figures in R [<xref ref-type="bibr" rid="pgen.1006915.ref062">62</xref>] and the script used to get the sequence context of each mutation are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/cegamorim/PopGenHumDisease">https://github.com/cegamorim/PopGenHumDisease</ext-link>. The code to run the simulations is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/sellalab/ForwardSimulator">https://github.com/sellalab/ForwardSimulator</ext-link>. Allele frequencies and other information for the disease mutations employed in the analyses are in <xref ref-type="supplementary-material" rid="pgen.1006915.s002">S2</xref> and <xref ref-type="supplementary-material" rid="pgen.1006915.s003">S3</xref> Tables.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pgen.1006915.ref001">
<label>1</label>
<mixed-citation publication-type="journal"><name><surname>Simons</surname><given-names>YB</given-names></name>, <name><surname>Turchin</surname><given-names>MC</given-names></name>, <name><surname>Pritchard</surname><given-names>JK</given-names></name>, <name><surname>Sella</surname><given-names>G</given-names></name> (<year>2014</year>) <article-title>The deleterious mutation load is insensitive to recent population history</article-title>. <source/>Nat Genet
<volume>46</volume>: <fpage>220</fpage>–<lpage>224</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.2896">10.1038/ng.2896</ext-link></comment>
<pub-id pub-id-type="pmid">24509481</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref002">
<label>2</label>
<mixed-citation publication-type="journal"><name><surname>Simons</surname><given-names>YB</given-names></name>, <name><surname>Sella</surname><given-names>G</given-names></name> (<year>2016</year>) <article-title>The impact of recent population history on the deleterious mutation load in humans and close evolutionary relatives</article-title>. <source/>Curr Opin Genet Dev
<volume>41</volume>: <fpage>150</fpage>–<lpage>158</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.gde.2016.09.006">10.1016/j.gde.2016.09.006</ext-link></comment>
<pub-id pub-id-type="pmid">27744216</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref003">
<label>3</label>
<mixed-citation publication-type="journal"><name><surname>Nei</surname><given-names>M</given-names></name> (<year>1968</year>) <article-title>The frequency distribution of lethal chromosomes in finite populations</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>60</volume>: <fpage>517</fpage>–<lpage>524</lpage>. <pub-id pub-id-type="pmid">5248809</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref004">
<label>4</label>
<mixed-citation publication-type="book"><name><surname>Gillespie</surname><given-names>JH</given-names></name> (<year>2004</year>) <source/>Population Genetics: A Concise Guide. <publisher-loc>Baltimore, MD</publisher-loc>: <publisher-name>Johns Hopkins University Press</publisher-name>.</mixed-citation>
</ref>
<ref id="pgen.1006915.ref005">
<label>5</label>
<mixed-citation publication-type="journal"><name><surname>Brandvain</surname><given-names>Y</given-names></name>, <name><surname>Wright</surname><given-names>SI</given-names></name> (<year>2016</year>) <article-title>The Limits of Natural Selection in a Nonequilibrium World</article-title>. <source/>Trends Genet
<volume>32</volume>: <fpage>201</fpage>–<lpage>210</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tig.2016.01.004">10.1016/j.tig.2016.01.004</ext-link></comment>
<pub-id pub-id-type="pmid">26874998</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref006">
<label>6</label>
<mixed-citation publication-type="journal"><name><surname>Balick</surname><given-names>DJ</given-names></name>, <name><surname>Do</surname><given-names>R</given-names></name>, <name><surname>Cassa</surname><given-names>CA</given-names></name>, <name><surname>Reich</surname><given-names>D</given-names></name>, <name><surname>Sunyaev</surname><given-names>SR</given-names></name> (<year>2015</year>) <article-title>Dominance of Deleterious Alleles Controls the Response to a Population Bottleneck</article-title>. <source/>PLoS Genet
<volume>11</volume>: <fpage>e1005436</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pgen.1005436">10.1371/journal.pgen.1005436</ext-link></comment>
<pub-id pub-id-type="pmid">26317225</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref007">
<label>7</label>
<mixed-citation publication-type="journal"><name><surname>Beauchamp</surname><given-names>KA</given-names></name>, <name><surname>Muzzey</surname><given-names>D</given-names></name>, <name><surname>Wong</surname><given-names>KK</given-names></name>, <name><surname>Hogan</surname><given-names>GJ</given-names></name>, <name><surname>Karimi</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Systematic Design and Comparison of Expanded Carrier Screening Panels</article-title>. <source/>Genet Med—ePub ahead of print</mixed-citation>
</ref>
<ref id="pgen.1006915.ref008">
<label>8</label>
<mixed-citation publication-type="journal"><name><surname>Clark</surname><given-names>AG</given-names></name> (<year>1998</year>) <article-title>Mutation-selection balance with multiple alleles</article-title>. <source/>Genetica
<volume>102–103</volume>: <fpage>41</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="pmid">9720270</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref009">
<label>9</label>
<mixed-citation publication-type="book"><name><surname>Crow</surname><given-names>JF</given-names></name>, <name><surname>Kimura</surname><given-names>M</given-names></name> (<year>1970</year>) <source/>Introduction to Population Genetics Theory
<publisher-loc>New York</publisher-loc>: <publisher-name>Harper &amp; Row Publishers</publisher-name>. 591 p.</mixed-citation>
</ref>
<ref id="pgen.1006915.ref010">
<label>10</label>
<mixed-citation publication-type="journal"><name><surname>Cormet-Boyaka</surname><given-names>E</given-names></name>, <name><surname>Jablonsky</surname><given-names>M</given-names></name>, <name><surname>Naren</surname><given-names>AP</given-names></name>, <name><surname>Jackson</surname><given-names>PL</given-names></name>, <name><surname>Muccio</surname><given-names>DD</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Rescuing cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by transcomplementation</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>101</volume>: <fpage>8221</fpage>–<lpage>8226</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.0400459101">10.1073/pnas.0400459101</ext-link></comment>
<pub-id pub-id-type="pmid">15141088</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref011">
<label>11</label>
<mixed-citation publication-type="journal"><name><surname>Rapino</surname><given-names>D</given-names></name>, <name><surname>Sabirzhanova</surname><given-names>I</given-names></name>, <name><surname>Lopes-Pacheco</surname><given-names>M</given-names></name>, <name><surname>Grover</surname><given-names>R</given-names></name>, <name><surname>Guggino</surname><given-names>WB</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation</article-title>. <source/>PLoS One
<volume>10</volume>: <fpage>e0119796</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0119796">10.1371/journal.pone.0119796</ext-link></comment>
<pub-id pub-id-type="pmid">25799511</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref012">
<label>12</label>
<mixed-citation publication-type="journal"><name><surname>Andressoo</surname><given-names>JO</given-names></name>, <name><surname>Jans</surname><given-names>J</given-names></name>, <name><surname>de Wit</surname><given-names>J</given-names></name>, <name><surname>Coin</surname><given-names>F</given-names></name>, <name><surname>Hoogstraten</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Rescue of progeria in trichothiodystrophy by homozygous lethal Xpd alleles</article-title>. <source/>PLoS Biol
<volume>4</volume>: <fpage>e322</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pbio.0040322">10.1371/journal.pbio.0040322</ext-link></comment>
<pub-id pub-id-type="pmid">17020410</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref013">
<label>13</label>
<mixed-citation publication-type="journal"><name><surname>Gallati</surname><given-names>S</given-names></name> (<year>2014</year>) <article-title>Disease-modifying genes and monogenic disorders: experience in cystic fibrosis</article-title>. <source/>Appl Clin Genet
<volume>7</volume>: <fpage>133</fpage>–<lpage>146</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2147/TACG.S18675">10.2147/TACG.S18675</ext-link></comment>
<pub-id pub-id-type="pmid">25053892</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref014">
<label>14</label>
<mixed-citation publication-type="journal"><name><surname>Corvol</surname><given-names>H</given-names></name>, <name><surname>Blackman</surname><given-names>SM</given-names></name>, <name><surname>Boelle</surname><given-names>PY</given-names></name>, <name><surname>Gallins</surname><given-names>PJ</given-names></name>, <name><surname>Pace</surname><given-names>RG</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis</article-title>. <source/>Nat Commun
<volume>6</volume>: <fpage>8382</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ncomms9382">10.1038/ncomms9382</ext-link></comment>
<pub-id pub-id-type="pmid">26417704</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref015">
<label>15</label>
<mixed-citation publication-type="journal"><name><surname>Habara</surname><given-names>A</given-names></name>, <name><surname>Steinberg</surname><given-names>MH</given-names></name> (<year>2016</year>) <article-title>Minireview: Genetic basis of heterogeneity and severity in sickle cell disease</article-title>. <source/>Exp Biol Med (Maywood)
<volume>241</volume>: <fpage>689</fpage>–<lpage>696</lpage>.<pub-id pub-id-type="pmid">26936084</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref016">
<label>16</label>
<mixed-citation publication-type="journal"><name><surname>Hedrick</surname><given-names>PW</given-names></name> (<year>2011</year>) <article-title>Population genetics of malaria resistance in humans</article-title>. <source/>Heredity (Edinb)
<volume>107</volume>: <fpage>283</fpage>–<lpage>304</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/hdy.2011.16">10.1038/hdy.2011.16</ext-link></comment>
<pub-id pub-id-type="pmid">21427751</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref017">
<label>17</label>
<mixed-citation publication-type="journal"><name><surname>Chong</surname><given-names>JX</given-names></name>, <name><surname>Buckingham</surname><given-names>KJ</given-names></name>, <name><surname>Jhangiani</surname><given-names>SN</given-names></name>, <name><surname>Boehm</surname><given-names>C</given-names></name>, <name><surname>Sobreira</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities</article-title>. <source/>Am J Hum Genet
<volume>97</volume>: <fpage>199</fpage>–<lpage>215</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ajhg.2015.06.009">10.1016/j.ajhg.2015.06.009</ext-link></comment>
<pub-id pub-id-type="pmid">26166479</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref018">
<label>18</label>
<mixed-citation publication-type="journal"><name><surname>Kong</surname><given-names>A</given-names></name>, <name><surname>Frigge</surname><given-names>ML</given-names></name>, <name><surname>Masson</surname><given-names>G</given-names></name>, <name><surname>Besenbacher</surname><given-names>S</given-names></name>, <name><surname>Sulem</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Rate of de novo mutations and the importance of father's age to disease risk</article-title>. <source/>Nature
<volume>488</volume>: <fpage>471</fpage>–<lpage>475</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature11396">10.1038/nature11396</ext-link></comment>
<pub-id pub-id-type="pmid">22914163</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref019">
<label>19</label>
<mixed-citation publication-type="journal"><name><surname>Turner</surname><given-names>TN</given-names></name>, <name><surname>Douville</surname><given-names>C</given-names></name>, <name><surname>Kim</surname><given-names>D</given-names></name>, <name><surname>Stenson</surname><given-names>PD</given-names></name>, <name><surname>Cooper</surname><given-names>DN</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Proteins linked to autosomal dominant and autosomal recessive disorders harbor characteristic rare missense mutation distribution patterns</article-title>. <source/>Hum Mol Genet
<volume>24</volume>: <fpage>5995</fpage>–<lpage>6002</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/hmg/ddv309">10.1093/hmg/ddv309</ext-link></comment>
<pub-id pub-id-type="pmid">26246501</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref020">
<label>20</label>
<mixed-citation publication-type="journal"><name><surname>Haque</surname><given-names>IS</given-names></name>, <name><surname>Lazarin</surname><given-names>GA</given-names></name>, <name><surname>Kang</surname><given-names>H</given-names></name>, <name><surname>Evans</surname><given-names>EA</given-names></name>, <name><surname>Goldberg</surname><given-names>JD</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Modeled fetal risk of genetic diseases identified by expanded carrier screening</article-title>. <source/>JAMA
<volume>316</volume>: <fpage>734</fpage>–<lpage>742</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2016.11139">10.1001/jama.2016.11139</ext-link></comment>
<pub-id pub-id-type="pmid">27533158</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref021">
<label>21</label>
<mixed-citation publication-type="journal"><name><surname>Cooper</surname><given-names>DN</given-names></name>, <name><surname>Youssoufian</surname><given-names>H</given-names></name> (<year>1988</year>) <article-title>The CpG dinucleotide and human genetic disease</article-title>. <source/>Hum Genet
<volume>78</volume>: <fpage>151</fpage>–<lpage>155</lpage>. <pub-id pub-id-type="pmid">3338800</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref022">
<label>22</label>
<mixed-citation publication-type="journal"><name><surname>Akalin</surname><given-names>N</given-names></name>, <name><surname>Zietkiewicz</surname><given-names>E</given-names></name>, <name><surname>Makalowski</surname><given-names>W</given-names></name>, <name><surname>Labuda</surname><given-names>D</given-names></name> (<year>1994</year>) <article-title>Are CpG sites mutation hot spots in the dystrophin gene?</article-title>
<source/>Hum Mol Genet
<volume>3</volume>.</mixed-citation>
</ref>
<ref id="pgen.1006915.ref023">
<label>23</label>
<mixed-citation publication-type="journal"><name><surname>Lek</surname><given-names>M</given-names></name>, <name><surname>Karczewski</surname><given-names>KJ</given-names></name>, <name><surname>Minikel</surname><given-names>EV</given-names></name>, <name><surname>Samocha</surname><given-names>KE</given-names></name>, <name><surname>Banks</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>. <source/>Nature
<volume>536</volume>: <fpage>285</fpage>–<lpage>291</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature19057">10.1038/nature19057</ext-link></comment>
<pub-id pub-id-type="pmid">27535533</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref024">
<label>24</label>
<mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>R</given-names></name>, <name><surname>Shi</surname><given-names>L</given-names></name>, <name><surname>Hakenberg</surname><given-names>J</given-names></name>, <name><surname>Naughton</surname><given-names>B</given-names></name>, <name><surname>Sklar</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases</article-title>. <source/>Nat Biotechnol
<volume>34</volume>: <fpage>531</fpage>–<lpage>538</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nbt.3514">10.1038/nbt.3514</ext-link></comment>
<pub-id pub-id-type="pmid">27065010</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref025">
<label>25</label>
<mixed-citation publication-type="journal"><name><surname>Tennessen</surname><given-names>JA</given-names></name>, <name><surname>Bigham</surname><given-names>AW</given-names></name>, <name><surname>O'Connor</surname><given-names>TD</given-names></name>, <name><surname>Fu</surname><given-names>W</given-names></name>, <name><surname>Kenny</surname><given-names>EE</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Evolution and functional impact of rare coding variation from deep sequencing of human exomes</article-title>. <source/>Science
<volume>337</volume>: <fpage>64</fpage>–<lpage>69</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1219240">10.1126/science.1219240</ext-link></comment>
<pub-id pub-id-type="pmid">22604720</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref026">
<label>26</label>
<mixed-citation publication-type="journal"><name><surname>Wright</surname><given-names>S</given-names></name> (<year>1937</year>) <article-title>The Distribution of Gene Frequencies in Populations</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>23</volume>: <fpage>307</fpage>–<lpage>320</lpage>. <pub-id pub-id-type="pmid">16577780</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref027">
<label>27</label>
<mixed-citation publication-type="journal"><name><surname>Harpak</surname><given-names>A</given-names></name>, <name><surname>Bhaskar</surname><given-names>A</given-names></name>, <name><surname>Pritchard</surname><given-names>JK</given-names></name> (<year>2016</year>) <article-title>Mutation Rate Variation is a Primary Determinant of the Distribution of Allele Frequencies in Humans</article-title>. <source/>PLoS Genet
<volume>12</volume>: <fpage>e1006489</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pgen.1006489">10.1371/journal.pgen.1006489</ext-link></comment>
<pub-id pub-id-type="pmid">27977673</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref028">
<label>28</label>
<mixed-citation publication-type="journal"><name><surname>Browning</surname><given-names>Sharon R</given-names></name>, <name><surname>Browning</surname><given-names>Brian L</given-names></name> (<year>2015</year>) <article-title>Accurate Non-parametric Estimation of Recent Effective Population Size from Segments of Identity by Descent</article-title>. <source/>The American Journal of Human Genetics
<volume>97</volume>: <fpage>404</fpage>–<lpage>418</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ajhg.2015.07.012">10.1016/j.ajhg.2015.07.012</ext-link></comment>
<pub-id pub-id-type="pmid">26299365</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref029">
<label>29</label>
<mixed-citation publication-type="journal"><name><surname>Reich</surname><given-names>DE</given-names></name>, <name><surname>Lander</surname><given-names>ES</given-names></name> (<year>2001</year>) <article-title>On the allelic spectrum of human disease</article-title>. <source/>Trends Genet
<volume>17</volume>: <fpage>502</fpage>–<lpage>510</lpage>. <pub-id pub-id-type="pmid">11525833</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref030">
<label>30</label>
<mixed-citation publication-type="journal"><name><surname>Pritchard</surname><given-names>JK</given-names></name>, <name><surname>Cox</surname><given-names>NJ</given-names></name> (<year>2002</year>) <article-title>The allelic architecture of human disease genes: common disease-common variant…or not?</article-title>
<source/>Hum Mol Genet
<volume>11</volume>: <fpage>2417</fpage>–<lpage>2423</lpage>. <pub-id pub-id-type="pmid">12351577</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref031">
<label>31</label>
<mixed-citation publication-type="journal"><name><surname>Zwick</surname><given-names>ME</given-names></name>, <name><surname>Cutler</surname><given-names>DJ</given-names></name>, <name><surname>Chakravarti</surname><given-names>A</given-names></name> (<year>2000</year>) <article-title>Patterns of genetic variation in Mendelian and complex traits</article-title>. <source/>Annu Rev Genomics Hum Genet
<volume>1</volume>: <fpage>387</fpage>–<lpage>407</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1146/annurev.genom.1.1.387">10.1146/annurev.genom.1.1.387</ext-link></comment>
<pub-id pub-id-type="pmid">11701635</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref032">
<label>32</label>
<mixed-citation publication-type="journal"><name><surname>Cassa</surname><given-names>CA</given-names></name>, <name><surname>Weghorn</surname><given-names>D</given-names></name>, <name><surname>Balick</surname><given-names>DJ</given-names></name>, <name><surname>Jordan</surname><given-names>DM</given-names></name>, <name><surname>Nusinow</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Estimating the Selective Effect of Heterozygous Protein Truncating Variants from Human Exome Data</article-title>. <source/>Nat Genet
<volume>49</volume>: <fpage>806</fpage>–<lpage>810</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.3831">10.1038/ng.3831</ext-link></comment>
<pub-id pub-id-type="pmid">28369035</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref033">
<label>33</label>
<mixed-citation publication-type="journal"><collab>The Thousand Genomes Consortium</collab> (<year>2015</year>) <article-title>A global reference for human genetic variation</article-title>. <source/>Nature
<volume>526</volume>: <fpage>68</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature15393">10.1038/nature15393</ext-link></comment>
<pub-id pub-id-type="pmid">26432245</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref034">
<label>34</label>
<mixed-citation publication-type="journal"><name><surname>Neale</surname><given-names>BM</given-names></name>, <name><surname>Kou</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>Ma/'ayan</surname><given-names>A</given-names></name>, <name><surname>Samocha</surname><given-names>KE</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Patterns and rates of exonic de novo mutations in autism spectrum disorders</article-title>. <source/>Nature
<volume>485</volume>: <fpage>242</fpage>–<lpage>245</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature11011">10.1038/nature11011</ext-link></comment>
<pub-id pub-id-type="pmid">22495311</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref035">
<label>35</label>
<mixed-citation publication-type="journal"><name><surname>Fu</surname><given-names>W</given-names></name>, <name><surname>O'Connor</surname><given-names>T</given-names></name>, <name><surname>Jun</surname><given-names>G</given-names></name>, <name><surname>Kang</surname><given-names>H</given-names></name>, <name><surname>Abecasis</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants</article-title>. <source/>Nature
<volume>493</volume>: <fpage>216</fpage>–<lpage>220</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature11690">10.1038/nature11690</ext-link></comment>
<pub-id pub-id-type="pmid">23201682</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref036">
<label>36</label>
<mixed-citation publication-type="journal"><name><surname>Segurel</surname><given-names>L</given-names></name>, <name><surname>Wyman</surname><given-names>MJ</given-names></name>, <name><surname>Przeworski</surname><given-names>M</given-names></name> (<year>2014</year>) <article-title>Determinants of mutation rate variation in the human germline</article-title>. <source/>Annu Rev Genomics Hum Genet
<volume>15</volume>: <fpage>47</fpage>–<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1146/annurev-genom-031714-125740">10.1146/annurev-genom-031714-125740</ext-link></comment>
<pub-id pub-id-type="pmid">25000986</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref037">
<label>37</label>
<mixed-citation publication-type="journal"><name><surname>Lohmueller</surname><given-names>KE</given-names></name>, <name><surname>Indap</surname><given-names>AR</given-names></name>, <name><surname>Schmidt</surname><given-names>S</given-names></name>, <name><surname>Boyko</surname><given-names>AR</given-names></name>, <name><surname>Hernandez</surname><given-names>RD</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Proportionally more deleterious genetic variation in European than in African populations</article-title>. <source/>Nature
<volume>451</volume>: <fpage>994</fpage>–<lpage>997</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature06611">10.1038/nature06611</ext-link></comment>
<pub-id pub-id-type="pmid">18288194</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref038">
<label>38</label>
<mixed-citation publication-type="journal"><name><surname>Peischl</surname><given-names>S</given-names></name>, <name><surname>Dupanloup</surname><given-names>I</given-names></name>, <name><surname>Bosshard</surname><given-names>L</given-names></name>, <name><surname>Excoffier</surname><given-names>L</given-names></name> (<year>2016</year>) <article-title>Genetic surfing in human populations: from genes to genomes</article-title>. <source/>Curr Opin Genet Dev
<volume>41</volume>: <fpage>53</fpage>–<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.gde.2016.08.003">10.1016/j.gde.2016.08.003</ext-link></comment>
<pub-id pub-id-type="pmid">27584859</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref039">
<label>39</label>
<mixed-citation publication-type="journal"><name><surname>Pritchard</surname><given-names>JK</given-names></name>, <name><surname>Cox</surname><given-names>NJ</given-names></name> (<year>2002</year>) <article-title>The allelic architecture of human disease genes: common disease-common variant…or not?</article-title>
<pub-id pub-id-type="pmid">12351577</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref040">
<label>40</label>
<mixed-citation publication-type="journal"><name><surname>Aggarwala</surname><given-names>V</given-names></name>, <name><surname>Voight</surname><given-names>BF</given-names></name> (<year>2016</year>) <article-title>An expanded sequence context model broadly explains variability in polymorphism levels across the human genome</article-title>. <source/>Nat Genet
<volume>48</volume>: <fpage>349</fpage>–<lpage>355</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.3511">10.1038/ng.3511</ext-link></comment>
<pub-id pub-id-type="pmid">26878723</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref041">
<label>41</label>
<mixed-citation publication-type="journal"><name><surname>Hodgkinson</surname><given-names>A</given-names></name>, <name><surname>Eyre-Walker</surname><given-names>A</given-names></name>
<article-title>Variation in the mutation rate across mammalian genomes</article-title>. <source/>Nat Rev Genet
<volume>12</volume>: <fpage>756</fpage>–<lpage>766</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrg3098">10.1038/nrg3098</ext-link></comment>
<pub-id pub-id-type="pmid">21969038</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref042">
<label>42</label>
<mixed-citation publication-type="journal"><name><surname>Moorjani</surname><given-names>P</given-names></name>, <name><surname>Amorim</surname><given-names>CE</given-names></name>, <name><surname>Arndt</surname><given-names>PF</given-names></name>, <name><surname>Przeworski</surname><given-names>M</given-names></name> (<year>2016</year>) <article-title>Variation in the molecular clock of primates</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>113</volume>: <fpage>10607</fpage>–<lpage>10612</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1600374113">10.1073/pnas.1600374113</ext-link></comment>
<pub-id pub-id-type="pmid">27601674</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref043">
<label>43</label>
<mixed-citation publication-type="journal"><name><surname>Kamphans</surname><given-names>T</given-names></name>, <name><surname>Sabri</surname><given-names>P</given-names></name>, <name><surname>Zhu</surname><given-names>N</given-names></name>, <name><surname>Heinrich</surname><given-names>V</given-names></name>, <name><surname>Mundlos</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Filtering for compound heterozygous sequence variants in non-consanguineous pedigrees</article-title>. <source/>PLoS One
<volume>8</volume>: <fpage>e70151</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0070151">10.1371/journal.pone.0070151</ext-link></comment>
<pub-id pub-id-type="pmid">23940540</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref044">
<label>44</label>
<mixed-citation publication-type="journal"><name><surname>Burkhart</surname><given-names>BD</given-names></name>, <name><surname>Montgomery</surname><given-names>E</given-names></name>, <name><surname>Langley</surname><given-names>CH</given-names></name>, <name><surname>Voelker</surname><given-names>RA</given-names></name> (<year>1984</year>) <article-title>Characterization of Allozyme Null and Low Activity Alleles from Two Natural Populations of DROSOPHILA MELANOGASTER</article-title>. <source/>Genetics
<volume>107</volume>: <fpage>295</fpage>–<lpage>306</lpage>. <pub-id pub-id-type="pmid">17246217</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref045">
<label>45</label>
<mixed-citation publication-type="journal"><name><surname>Xue</surname><given-names>Y</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Ayub</surname><given-names>Q</given-names></name>, <name><surname>Huang</surname><given-names>N</given-names></name>, <name><surname>Ball</surname><given-names>EV</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Deleterious- and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing</article-title>. <source/>Am J Hum Genet
<volume>91</volume>: <fpage>1022</fpage>–<lpage>1032</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ajhg.2012.10.015">10.1016/j.ajhg.2012.10.015</ext-link></comment>
<pub-id pub-id-type="pmid">23217326</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref046">
<label>46</label>
<mixed-citation publication-type="journal"><name><surname>Piton</surname><given-names>A</given-names></name>, <name><surname>Redin</surname><given-names>C</given-names></name>, <name><surname>Mandel</surname><given-names>JL</given-names></name> (<year>2013</year>) <article-title>XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing</article-title>. <source/>Am J Hum Genet
<volume>93</volume>: <fpage>368</fpage>–<lpage>383</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ajhg.2013.06.013">10.1016/j.ajhg.2013.06.013</ext-link></comment>
<pub-id pub-id-type="pmid">23871722</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref047">
<label>47</label>
<mixed-citation publication-type="journal"><name><surname>Gazave</surname><given-names>E</given-names></name>, <name><surname>Ma</surname><given-names>L</given-names></name>, <name><surname>Chang</surname><given-names>D</given-names></name>, <name><surname>Coventry</surname><given-names>A</given-names></name>, <name><surname>Gao</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Neutral genomic regions refine models of recent rapid human population growth</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>111</volume>: <fpage>757</fpage>–<lpage>762</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1310398110">10.1073/pnas.1310398110</ext-link></comment>
<pub-id pub-id-type="pmid">24379384</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref048">
<label>48</label>
<mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>F</given-names></name>, <name><surname>Keinan</surname><given-names>A</given-names></name> (<year>2016</year>) <article-title>Explosive genetic evidence for explosive human population growth</article-title>. <source/>Curr Opin Genet Dev
<volume>41</volume>: <fpage>130</fpage>–<lpage>139</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.gde.2016.09.002">10.1016/j.gde.2016.09.002</ext-link></comment>
<pub-id pub-id-type="pmid">27710906</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref049">
<label>49</label>
<mixed-citation publication-type="journal"><name><surname>Wright</surname><given-names>S</given-names></name> (<year>1931</year>) <article-title>Evolution in Mendelian populations</article-title>. <source/>Genetics
<volume>16</volume>: <fpage>97</fpage>–<lpage>159</lpage>. <pub-id pub-id-type="pmid">17246615</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref050">
<label>50</label>
<mixed-citation publication-type="journal"><name><surname>Ober</surname><given-names>C</given-names></name>, <name><surname>Hyslop</surname><given-names>T</given-names></name>, <name><surname>Hauck</surname><given-names>WW</given-names></name> (<year>1999</year>) <article-title>Inbreeding Effects on Fertility in Humans: Evidence for Reproductive Compensation</article-title>. <source/>The American Journal of Human Genetics
<volume>64</volume>: <fpage>225</fpage>–<lpage>231</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/302198">10.1086/302198</ext-link></comment>
<pub-id pub-id-type="pmid">9915962</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref051">
<label>51</label>
<mixed-citation publication-type="journal"><name><surname>Gabriel</surname><given-names>SE</given-names></name>, <name><surname>Brigman</surname><given-names>KN</given-names></name>, <name><surname>Koller</surname><given-names>BH</given-names></name>, <name><surname>Boucher</surname><given-names>RC</given-names></name>, <name><surname>Stutts</surname><given-names>MJ</given-names></name> (<year>1994</year>) <article-title>Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model</article-title>. <source/>Science
<volume>266</volume>: <fpage>107</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="pmid">7524148</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref052">
<label>52</label>
<mixed-citation publication-type="journal"><name><surname>Wagener</surname><given-names>D</given-names></name>, <name><surname>Cavalli-Sforza</surname><given-names>LL</given-names></name>, <name><surname>Barakat</surname><given-names>R</given-names></name> (<year>1978</year>) <article-title>Ethnic variation of genetic disease: roles of drift for recessive lethal genes</article-title>. <source/>American Journal of Human Genetics
<volume>30</volume>: <fpage>262</fpage>–<lpage>270</lpage>. <pub-id pub-id-type="pmid">677123</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref053">
<label>53</label>
<mixed-citation publication-type="journal"><name><surname>Quinton</surname><given-names>PM</given-names></name> (<year>1994</year>) <article-title>Human genetics. What is good about cystic fibrosis?</article-title>
<source/>Curr Biol
<volume>4</volume>: <fpage>742</fpage>–<lpage>743</lpage>. <pub-id pub-id-type="pmid">7525005</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref054">
<label>54</label>
<mixed-citation publication-type="journal"><name><surname>Chakravarti</surname><given-names>A</given-names></name>, <name><surname>Chakraborty</surname><given-names>R</given-names></name> (<year>1978</year>) <article-title>Elevated frequency of Tay-Sachs disease among Ashkenazic Jews unlikely by genetic drift alone</article-title>. <source/>American Journal of Human Genetics
<volume>30</volume>: <fpage>256</fpage>–<lpage>261</lpage>. <pub-id pub-id-type="pmid">677122</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref055">
<label>55</label>
<mixed-citation publication-type="journal"><name><surname>Ewens</surname><given-names>WJ</given-names></name> (<year>1978</year>) <article-title>Tay-Sachs disease and theoretical population genetics</article-title>. <source/>American Journal of Human Genetics
<volume>30</volume>: <fpage>328</fpage>–<lpage>329</lpage>. <pub-id pub-id-type="pmid">677129</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref056">
<label>56</label>
<mixed-citation publication-type="journal"><name><surname>Landrum</surname><given-names>MJ</given-names></name>, <name><surname>Lee</surname><given-names>JM</given-names></name>, <name><surname>Riley</surname><given-names>GR</given-names></name>, <name><surname>Jang</surname><given-names>W</given-names></name>, <name><surname>Rubinstein</surname><given-names>WS</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>ClinVar: public archive of relationships among sequence variation and human phenotype</article-title>. <source/>Nucleic acids research
<volume>42</volume>: <fpage>D980</fpage>–<lpage>D985</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/nar/gkt1113">10.1093/nar/gkt1113</ext-link></comment>
<pub-id pub-id-type="pmid">24234437</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref057">
<label>57</label>
<mixed-citation publication-type="journal"><name><surname>Eppig</surname><given-names>JT</given-names></name>, <name><surname>Blake</surname><given-names>JA</given-names></name>, <name><surname>Bult</surname><given-names>CJ</given-names></name>, <name><surname>Kadin</surname><given-names>JA</given-names></name>, <name><surname>Richardson</surname><given-names>JE</given-names></name> (<year>2015</year>) <article-title>The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease</article-title>. <source/>Nucleic Acids Res
<volume>43</volume>: <fpage>D726</fpage>–<lpage>736</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/nar/gku967">10.1093/nar/gku967</ext-link></comment>
<pub-id pub-id-type="pmid">25348401</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref058">
<label>58</label>
<mixed-citation publication-type="journal"><name><surname>Gravel</surname><given-names>S</given-names></name>, <name><surname>Henn</surname><given-names>BM</given-names></name>, <name><surname>Gutenkunst</surname><given-names>RN</given-names></name>, <name><surname>Indap</surname><given-names>AR</given-names></name>, <name><surname>Marth</surname><given-names>GT</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Demographic history and rare allele sharing among human populations</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>108</volume>: <fpage>11983</fpage>–<lpage>11988</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1019276108">10.1073/pnas.1019276108</ext-link></comment>
<pub-id pub-id-type="pmid">21730125</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref059">
<label>59</label>
<mixed-citation publication-type="journal"><name><surname>Mugal</surname><given-names>CF</given-names></name>, <name><surname>Ellegren</surname><given-names>H</given-names></name> (<year>2011</year>) <article-title>Substitution rate variation at human CpG sites correlates with non-CpG divergence, methylation level and GC content</article-title>. <source/>Genome Biol
<volume>12</volume>: <fpage>R58</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/gb-2011-12-6-r58">10.1186/gb-2011-12-6-r58</ext-link></comment>
<pub-id pub-id-type="pmid">21696599</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref060">
<label>60</label>
<mixed-citation publication-type="journal"><name><surname>North</surname><given-names>BV</given-names></name>, <name><surname>Curtis</surname><given-names>D</given-names></name>, <name><surname>Sham</surname><given-names>PC</given-names></name> (<year>2002</year>) <article-title>A Note on the Calculation of Empirical Values from Monte Carlo Procedures</article-title>. <source/>The American Journal of Human Genetics
<volume>71</volume>: <fpage>439</fpage>–<lpage>441</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/341527">10.1086/341527</ext-link></comment>
<pub-id pub-id-type="pmid">12111669</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref061">
<label>61</label>
<mixed-citation publication-type="journal"><name><surname>Quinlan</surname><given-names>AR</given-names></name>, <name><surname>Hall</surname><given-names>IM</given-names></name> (<year>2010</year>) <article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title>. <source/>Bioinformatics
<volume>26</volume>: <fpage>841</fpage>–<lpage>842</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/bioinformatics/btq033">10.1093/bioinformatics/btq033</ext-link></comment>
<pub-id pub-id-type="pmid">20110278</pub-id></mixed-citation>
</ref>
<ref id="pgen.1006915.ref062">
<label>62</label>
<mixed-citation publication-type="other">R Core Team (2015) R: A Language and Environment for Statistical Computing. Vienna, Austria.</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>